| Variant RS ID |
Variant gene |
Pathway |
Up/Down |
Location |
Chromosome |
Start position |
End position |
Potentially relevant drug(s) |
| rs145031900 |
EBP |
Cholesterol synthesis |
Down |
Intergenic |
chrX |
48534683 |
48534683 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs7052966 |
PDHA1 |
Citric acid cycle |
Up |
Intergenic |
chrX |
19206580 |
19206580 |
pazopanib |
| rs145031900 |
EBP |
Cholesterol synthesis |
Up |
Intergenic |
chrX |
48534683 |
48534683 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs34464675 |
CLCN5 |
Chloride transmembrane transport |
Down |
Exonic |
chrX |
50081733 |
50081733 |
ponatinib;sunitinib;vandetanib |
| rs17308201 |
AMOT |
Hippo signaling |
Down |
Intergenic |
chrX |
113015898 |
113015898 |
pazopanib |
| rs375913710 |
TMOD1 |
Myofibril formation |
Up |
Exonic |
chr9 |
97568978 |
97568978 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs375913710 |
TMOD1 |
Myofibril formation |
Down |
Exonic |
chr9 |
97568978 |
97568978 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs117643807 |
TMOD1 |
Myofibril formation |
Up |
Intronic |
chr9 |
97590492 |
97590492 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs10982602 |
TMOD1 |
Myofibril formation |
Up |
Intronic |
chr9 |
97537493 |
97537493 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs12551047 |
CRB2 |
Hippo signaling |
Down |
Exonic |
chr9 |
123356321 |
123356321 |
pazopanib |
| rs2488601 |
CRB2 |
Hippo signaling |
Down |
Exonic |
chr9 |
123373436 |
123373436 |
pazopanib |
| rs2488602 |
CRB2 |
Hippo signaling |
Down |
Exonic |
chr9 |
123371268 |
123371268 |
pazopanib |
| rs11243698 |
ASS1 |
Aspartate and arginine metabolism |
Down |
Intergenic |
chr9 |
130538637 |
130538637 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs2808415 |
CRB2 |
Hippo signaling |
Down |
Exonic |
chr9 |
123363039 |
123363039 |
pazopanib |
| rs75370841 |
CRB2 |
Hippo signaling |
Down |
Exonic |
chr9 |
123371518 |
123371518 |
pazopanib |
| rs62544641 |
AQP3 |
Water transmembrane transport |
Up |
Intergenic |
chr9 |
33410727 |
33410727 |
afatinib;cetuximab;gefitinib;vemurafenib |
| rs76971409 |
AQP3 |
Water transmembrane transport |
Up |
Intergenic |
chr9 |
33404610 |
33404610 |
afatinib;cetuximab;gefitinib;vemurafenib |
| rs45456595 |
CDKN2A |
Restriction point |
Up |
Exonic |
chr9 |
21974641 |
21974641 |
sunitinib;vandetanib |
| rs121964976 |
GLDC |
Serine and glycine metabolism |
Down |
Exonic |
chr9 |
6589230 |
6589230 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs41274244 |
TMOD1 |
Myofibril formation |
Down |
Utr5 |
chr9 |
97524149 |
97524149 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs62544641 |
AQP7 |
Water transmembrane transport |
Up |
Intergenic |
chr9 |
33410727 |
33410727 |
afatinib;cetuximab;gefitinib;vemurafenib |
| rs117643807 |
TMOD1 |
Myofibril formation |
Down |
Intronic |
chr9 |
97590492 |
97590492 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs41274244 |
TMOD1 |
Myofibril formation |
Up |
Utr5 |
chr9 |
97524149 |
97524149 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs10982602 |
TMOD1 |
Myofibril formation |
Down |
Intronic |
chr9 |
97537493 |
97537493 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs147149845 |
PSAT1 |
Serine and glycine metabolism |
Down |
Intergenic |
chr9 |
78350031 |
78350031 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs112574168 |
GLDC |
Serine and glycine metabolism |
Down |
Intergenic |
chr9 |
6509277 |
6509277 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs78363712 |
ABCA1 |
Cellular cholesterol uptake and efflux |
Down |
Intergenic |
chr9 |
105220509 |
105220509 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs35819696 |
ABCA1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr9 |
104826965 |
104826965 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs33918808 |
ABCA1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr9 |
104817351 |
104817351 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs2274873 |
ABCA1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr9 |
104840397 |
104840397 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs2066716 |
ABCA1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr9 |
104806424 |
104806424 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs2066715 |
ABCA1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr9 |
104825752 |
104825752 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs117310474 |
ABCA1 |
Cellular cholesterol uptake and efflux |
Down |
Intergenic |
chr9 |
105116414 |
105116414 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs117881899 |
ABCA1 |
Cellular cholesterol uptake and efflux |
Down |
Intronic |
chr9 |
104920916 |
104920916 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs1836064621 |
ABCA1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr9 |
104858690 |
104858690 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs642636 |
AQP7 |
Water transmembrane transport |
Down |
Exonic |
chr9 |
33395198 |
33395198 |
dabrafenib;pazopanib;ponatinib |
| rs2004746 |
PSAT1 |
Serine and glycine metabolism |
Down |
Intergenic |
chr9 |
78564192 |
78564192 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs71496237 |
PSAT1 |
Serine and glycine metabolism |
Down |
Intergenic |
chr9 |
78787940 |
78787940 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs117699195 |
SLC24A2 |
Potassium transmembrane transport |
Up |
Intergenic |
chr9 |
19897219 |
19897219 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs13289273 |
GLDC |
Serine and glycine metabolism |
Down |
Exonic |
chr9 |
6620216 |
6620216 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs2232629 |
LCN2 |
Cellular iron uptake and export |
Up |
Intronic |
chr9 |
128152155 |
128152155 |
crizotinib;imatinib;ruxolitinib |
| rs76971409 |
AQP7 |
Water transmembrane transport |
Down |
Intergenic |
chr9 |
33404610 |
33404610 |
dabrafenib;pazopanib;ponatinib |
| rs150015624 |
LCN2 |
Cellular iron uptake and export |
Up |
Intergenic |
chr9 |
128140494 |
128140494 |
crizotinib;imatinib;ruxolitinib |
| rs2004746 |
PSAT1 |
Serine and glycine metabolism |
Up |
Intergenic |
chr9 |
78564192 |
78564192 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs147149845 |
PSAT1 |
Serine and glycine metabolism |
Up |
Intergenic |
chr9 |
78350031 |
78350031 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs13289273 |
GLDC |
Serine and glycine metabolism |
Up |
Exonic |
chr9 |
6620216 |
6620216 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs121964976 |
GLDC |
Serine and glycine metabolism |
Up |
Exonic |
chr9 |
6589230 |
6589230 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs112574168 |
GLDC |
Serine and glycine metabolism |
Up |
Intergenic |
chr9 |
6509277 |
6509277 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs3739480 |
SLC24A2 |
Potassium transmembrane transport |
Up |
Exonic |
chr9 |
19516282 |
19516282 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs45456595 |
CDKN2A |
Restriction point |
Down |
Exonic |
chr9 |
21974641 |
21974641 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs79720897 |
VLDLR |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr9 |
2648747 |
2648747 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs642636 |
AQP7 |
Water transmembrane transport |
Up |
Exonic |
chr9 |
33395198 |
33395198 |
afatinib;cetuximab;gefitinib;vemurafenib |
| rs76971409 |
AQP3 |
Water transmembrane transport |
Down |
Intergenic |
chr9 |
33404610 |
33404610 |
dabrafenib;pazopanib;ponatinib |
| rs71496237 |
PSAT1 |
Serine and glycine metabolism |
Up |
Intergenic |
chr9 |
78787940 |
78787940 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs117186988 |
FBP1 |
Glycolysis and Gluconeogenesis |
Down |
Intergenic |
chr9 |
94675833 |
94675833 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs386736436 |
FBP1 |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr9 |
94606867 |
94606867 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs62544641 |
AQP3 |
Water transmembrane transport |
Down |
Intergenic |
chr9 |
33410727 |
33410727 |
dabrafenib;pazopanib;ponatinib |
| rs76971409 |
AQP7 |
Water transmembrane transport |
Up |
Intergenic |
chr9 |
33404610 |
33404610 |
afatinib;cetuximab;gefitinib;vemurafenib |
| rs62544641 |
AQP7 |
Water transmembrane transport |
Down |
Intergenic |
chr9 |
33410727 |
33410727 |
dabrafenib;pazopanib;ponatinib |
| rs567355202 |
MSR1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr8 |
16155124 |
16155124 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs1136159 |
PLAT |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
Exonic |
chr8 |
42179059 |
42179059 |
axitinib;bosutinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs2020921 |
PLAT |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
Exonic |
chr8 |
42187447 |
42187447 |
axitinib;bosutinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs4731 |
FDFT1 |
Cholesterol synthesis |
Down |
Exonic |
chr8 |
11808828 |
11808828 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs11785005 |
MSR1 |
Cellular cholesterol uptake and efflux |
Down |
Intergenic |
chr8 |
15925961 |
15925961 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs4338104 |
MSR1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr8 |
16120554 |
16120554 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs904011 |
FDFT1 |
Cholesterol synthesis |
Down |
Exonic |
chr8 |
11826144 |
11826144 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs528854802 |
MSR1 |
Cellular cholesterol uptake and efflux |
Down |
Intergenic |
chr8 |
15925063 |
15925066 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs904011 |
FDFT1 |
Cholesterol synthesis |
Up |
Exonic |
chr8 |
11826144 |
11826144 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs4731 |
FDFT1 |
Cholesterol synthesis |
Up |
Exonic |
chr8 |
11808828 |
11808828 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs2942025 |
LYN |
Granulocyte-colony stimulating factor receptor signaling |
Down |
Intergenic |
chr8 |
56043824 |
56043824 |
axitinib;bosutinib;ruxolitinib;tofacitinib;vemurafenib |
| rs79522313 |
COL14A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Intronic |
chr8 |
120320325 |
120320325 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs114262403 |
COL14A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr8 |
120231499 |
120231499 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs2305603 |
COL14A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr8 |
120243911 |
120243911 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs2305605 |
COL14A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr8 |
120247623 |
120247623 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs74514270 |
SLC7A2 |
Aspartate and arginine metabolism |
Down |
Exonic |
chr8 |
17558353 |
17558353 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs190002459 |
LYN |
Granulocyte-colony stimulating factor receptor signaling |
Up |
Intergenic |
chr8 |
56041375 |
56041375 |
bevacizumab;lapatinib;trastuzumab |
| rs2942025 |
LYN |
Granulocyte-colony stimulating factor receptor signaling |
Up |
Intergenic |
chr8 |
56043824 |
56043824 |
bevacizumab;lapatinib;trastuzumab |
| rs61753753 |
COL14A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr8 |
120225106 |
120225106 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs144254804 |
NEFM |
Axonal intermediate filament dynamics |
Up |
Intergenic |
chr8 |
24639120 |
24639120 |
afatinib;axitinib;cetuximab;ruxolitinib;vemurafenib |
| rs984537 |
NEFM |
Axonal intermediate filament dynamics |
Up |
Intergenic |
chr8 |
24804100 |
24804100 |
afatinib;axitinib;cetuximab;ruxolitinib;vemurafenib |
| rs190002459 |
LYN |
Granulocyte-colony stimulating factor receptor signaling |
Down |
Intergenic |
chr8 |
56041375 |
56041375 |
axitinib;bosutinib;ruxolitinib;tofacitinib;vemurafenib |
| rs28362692 |
AQP1 |
Water transmembrane transport |
Down |
Exonic |
chr7 |
30912043 |
30912043 |
dabrafenib;pazopanib;ponatinib |
| rs142773283 |
CFTR |
Chloride transmembrane transport |
Down |
Exonic |
chr7 |
117603729 |
117603729 |
ponatinib;sunitinib;vandetanib |
| rs3917507 |
PON1 |
Cellular cholesterol uptake and efflux |
Down |
Intronic |
chr7 |
95314572 |
95314572 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs73140762 |
PSPH |
Serine and glycine metabolism |
Down |
Intergenic |
chr7 |
56009242 |
56009242 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs145131675 |
PSPH |
Serine and glycine metabolism |
Down |
Intronic |
chr7 |
56019039 |
56019040 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs145131675 |
PSPH |
Serine and glycine metabolism |
Up |
Intronic |
chr7 |
56019039 |
56019040 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs76303215 |
LEP |
Leptin receptor signaling |
Down |
Intergenic |
chr7 |
128225115 |
128225115 |
axitinib;ruxolitinib;tofacitinib;vemurafenib |
| rs73140762 |
PSPH |
Serine and glycine metabolism |
Up |
Intergenic |
chr7 |
56009242 |
56009242 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs2107349 |
GJC3 |
Gap junction organization |
Down |
Intergenic |
chr7 |
99960817 |
99960817 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs28954118 |
LEP |
Leptin receptor signaling |
Down |
Utr3 |
chr7 |
128255129 |
128255129 |
axitinib;ruxolitinib;tofacitinib;vemurafenib |
| rs112440054 |
LEP |
Leptin receptor signaling |
Down |
Intergenic |
chr7 |
128231919 |
128231919 |
axitinib;ruxolitinib;tofacitinib;vemurafenib |
| rs76303215 |
LEP |
Leptin receptor signaling |
Up |
Intergenic |
chr7 |
128225115 |
128225115 |
lapatinib;trastuzumab |
| rs28954118 |
LEP |
Leptin receptor signaling |
Up |
Utr3 |
chr7 |
128255129 |
128255129 |
lapatinib;trastuzumab |
| rs112440054 |
LEP |
Leptin receptor signaling |
Up |
Intergenic |
chr7 |
128231919 |
128231919 |
lapatinib;trastuzumab |
| rs17879784 |
PON1 |
Cellular cholesterol uptake and efflux |
Down |
Intergenic |
chr7 |
95348139 |
95348139 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs1554545329 |
STEAP4 |
Cellular iron uptake and export |
Up |
Intergenic |
chr7 |
88319085 |
88319085 |
crizotinib;imatinib;ruxolitinib |
| rs1800130 |
CFTR |
Chloride transmembrane transport |
Down |
Exonic |
chr7 |
117642590 |
117642590 |
ponatinib;sunitinib;vandetanib |
| rs11766078 |
SLC25A13 |
Aspartate and arginine metabolism |
Down |
Intergenic |
chr7 |
96351293 |
96351293 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs28362692 |
AQP1 |
Water transmembrane transport |
Up |
Exonic |
chr7 |
30912043 |
30912043 |
afatinib;cetuximab;gefitinib;vemurafenib |
| rs144152588 |
GCK |
Glycolysis and Gluconeogenesis |
Down |
Intronic |
chr7 |
44165321 |
44165321 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs11557280 |
OGDH |
Citric acid cycle |
Up |
Exonic |
chr7 |
44645449 |
44645449 |
pazopanib |
| rs147248801 |
PDGFA |
Platelet-derived growth factor receptor signaling |
Down |
Intergenic |
chr7 |
452696 |
452696 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs4728329 |
AKR1B10 |
Polyol pathway |
Down |
Exonic |
chr7 |
134541075 |
134541075 |
bevacizumab |
| rs78777755 |
GCK |
Glycolysis and Gluconeogenesis |
Down |
Intronic |
chr7 |
44161323 |
44161323 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs77586333 |
SLC25A13 |
Aspartate and arginine metabolism |
Down |
Intronic |
chr7 |
96180624 |
96180624 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs76724683 |
INSIG1 |
Cholesterol-sensitive control of SREBP activation |
Up |
Intergenic |
chr7 |
155144608 |
155144608 |
lapatinib;pazopanib;ponatinib;sorafenib;sunitinib |
| rs76724683 |
INSIG1 |
Cholesterol-sensitive control of SREBP activation |
Down |
Intergenic |
chr7 |
155144608 |
155144608 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;gefitinib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs144723656 |
GCK |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr7 |
44149794 |
44149794 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs72907658 |
CYB5R4 |
Desaturation of fatty acids |
Up |
Intergenic |
chr6 |
83998130 |
83998130 |
dabrafenib;lapatinib;pazopanib;sorafenib |
| rs240410 |
COL12A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Intergenic |
chr6 |
75231023 |
75231023 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs72853846 |
CCND3 |
Restriction point |
Up |
Intronic |
chr6 |
41988040 |
41988040 |
sunitinib;vandetanib |
| rs6910140 |
COL9A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr6 |
70234554 |
70234554 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs9394855 |
CCND3 |
Restriction point |
Up |
Intronic |
chr6 |
42039339 |
42039339 |
sunitinib;vandetanib |
| rs3218102 |
CCND3 |
Restriction point |
Up |
Exonic |
chr6 |
41936045 |
41936045 |
sunitinib;vandetanib |
| rs2145047 |
CDKN1A |
Restriction point |
Up |
Intergenic |
chr6 |
36695875 |
36695875 |
sunitinib;vandetanib |
| rs35710072 |
COL12A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr6 |
75113656 |
75113656 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs112019887 |
COL19A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Intergenic |
chr6 |
69807543 |
69807543 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs34846477 |
COL12A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr6 |
75089136 |
75089136 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs607156 |
COL9A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr6 |
70272083 |
70272083 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs568980 |
COL9A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Intronic |
chr6 |
70231512 |
70231512 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs115784602 |
ALDH5A1 |
GABA metabolism |
Up |
Exonic |
chr6 |
24520491 |
24520491 |
axitinib;cabozantinib;imatinib;nilotinib;ruxolitinib;vemurafenib |
| rs2072650 |
COL9A1 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr6 |
70234582 |
70234582 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs2145047 |
CDKN1A |
Restriction point |
Down |
Intergenic |
chr6 |
36695875 |
36695875 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs3218102 |
CCND3 |
Restriction point |
Down |
Exonic |
chr6 |
41936045 |
41936045 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs145021414 |
SLC26A8 |
Chloride transmembrane transport |
Down |
Intronic |
chr6 |
35946157 |
35946157 |
ponatinib;sunitinib;vandetanib |
| rs61741366 |
SLC26A8 |
Chloride transmembrane transport |
Down |
Exonic |
chr6 |
35944079 |
35944079 |
ponatinib;sunitinib;vandetanib |
| rs57946868 |
GJA1 |
Gap junction organization |
Down |
Exonic |
chr6 |
121447564 |
121447564 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs9394855 |
CCND3 |
Restriction point |
Down |
Intronic |
chr6 |
42039339 |
42039339 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs117023196 |
CITED2 |
HIF-1 receptor signaling pathway |
Down |
Intergenic |
chr6 |
139317936 |
139317936 |
dabrafenib;pazopanib |
| rs72853846 |
CCND3 |
Restriction point |
Down |
Intronic |
chr6 |
41988040 |
41988040 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs200105216 |
AKAP12 |
Adrenergic receptor signaling |
Down |
Exonic |
chr6 |
151349056 |
151349056 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs41289373 |
AKAP12 |
Adrenergic receptor signaling |
Down |
Exonic |
chr6 |
151351935 |
151351935 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs750155367 |
MYLIP |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr6 |
16145242 |
16145242 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs75135631 |
MYLIP |
Cellular cholesterol uptake and efflux |
Down |
Intergenic |
chr6 |
15822420 |
15822420 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs78572856 |
MYLIP |
Cellular cholesterol uptake and efflux |
Down |
Intergenic |
chr6 |
15702676 |
15702676 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs542481082 |
EZR |
Adrenergic receptor signaling |
Down |
Exonic |
chr6 |
158767296 |
158767296 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs41273124 |
KCNK5 |
Potassium transmembrane transport |
Up |
Exonic |
chr6 |
39191296 |
39191296 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs35341741 |
AKAP12 |
Adrenergic receptor signaling |
Down |
Exonic |
chr6 |
151349555 |
151349555 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs34713284 |
AKAP12 |
Adrenergic receptor signaling |
Down |
Exonic |
chr6 |
151353135 |
151353135 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs145766573 |
AKAP12 |
Adrenergic receptor signaling |
Down |
Intronic |
chr6 |
151274778 |
151274778 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs142810400 |
AKAP12 |
Adrenergic receptor signaling |
Down |
Exonic |
chr6 |
151349521 |
151349521 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs13212161 |
AKAP12 |
Adrenergic receptor signaling |
Down |
Exonic |
chr6 |
151351150 |
151351150 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs833056 |
VEGFA |
Vascular endothelial growth factor receptor signaling |
Up |
Intergenic |
chr6 |
43725135 |
43725135 |
dabrafenib;pazopanib |
| rs116484285 |
VEGFA |
Vascular endothelial growth factor receptor signaling |
Down |
Intergenic |
chr6 |
43691090 |
43691090 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs2815092 |
KCNK5 |
Potassium transmembrane transport |
Up |
Intergenic |
chr6 |
39176149 |
39176149 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs149637286 |
KCNK5 |
Potassium transmembrane transport |
Up |
Intergenic |
chr6 |
39131175 |
39131175 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs833056 |
VEGFA |
Vascular endothelial growth factor receptor signaling |
Down |
Intergenic |
chr6 |
43725135 |
43725135 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs796051923 |
ARG1 |
Aspartate and arginine metabolism |
Down |
Exonic |
chr6 |
131579250 |
131579250 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs116484285 |
VEGFA |
Vascular endothelial growth factor receptor signaling |
Up |
Intergenic |
chr6 |
43691090 |
43691090 |
dabrafenib;pazopanib |
| rs61745231 |
HK3 |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr5 |
176881112 |
176881112 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs2229558 |
PDGFRB |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr5 |
150132844 |
150132844 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs2228440 |
PDGFRB |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr5 |
150117665 |
150117665 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs1368376 |
PDGFRB |
Platelet-derived growth factor receptor signaling |
Down |
Intronic |
chr5 |
150125764 |
150125764 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs79778505 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Down |
Intronic |
chr5 |
180641154 |
180641154 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs372902128 |
RGS14 |
Adrenergic receptor signaling |
Down |
Exonic |
chr5 |
177366969 |
177366969 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs78142149 |
PDE4D |
Adrenergic receptor signaling |
Down |
Intronic |
chr5 |
60439509 |
60439509 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs141123858 |
HK3 |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr5 |
176890835 |
176890835 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs145827614 |
HK3 |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr5 |
176881302 |
176881302 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs61749650 |
HK3 |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr5 |
176887059 |
176887059 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs530327370 |
SDHA |
Citric acid cycle |
Up |
Intergenic |
chr5 |
258862 |
258862 |
pazopanib |
| rs61758138 |
ANKHD1 |
Hippo signaling |
Down |
Exonic |
chr5 |
140436224 |
140436224 |
pazopanib |
| rs34675408 |
OSMR |
Oncostatin-M receptor signaling |
Down |
Exonic |
chr5 |
38883969 |
38883969 |
ruxolitinib;tofacitinib |
| rs35117676 |
OSMR |
Oncostatin-M receptor signaling |
Down |
Exonic |
chr5 |
38903980 |
38903980 |
ruxolitinib;tofacitinib |
| rs56257144 |
HMGCS1 |
Cholesterol synthesis |
Down |
Exonic |
chr5 |
43294090 |
43294090 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs55688950 |
ADCY2 |
Adrenergic receptor signaling |
Down |
Intronic |
chr5 |
7730842 |
7730843 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs61749651 |
HK3 |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr5 |
176887205 |
176887205 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs2288461 |
SDHA |
Citric acid cycle |
Up |
Intronic |
chr5 |
230865 |
230865 |
pazopanib |
| rs2228058 |
PTGER4 |
Prostaglandin E2 receptor signaling |
Down |
Exonic |
chr5 |
40681152 |
40681152 |
dasatinib;rituximab;ruxolitinib;vemurafenib |
| rs62342974 |
ADCY2 |
Adrenergic receptor signaling |
Down |
Intronic |
chr5 |
7566060 |
7566060 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs111407669 |
ADCY2 |
Adrenergic receptor signaling |
Down |
Intronic |
chr5 |
7567658 |
7567658 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs79778505 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Up |
Intronic |
chr5 |
180641154 |
180641154 |
dabrafenib;pazopanib |
| rs79620092 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Up |
Exonic |
chr5 |
180603322 |
180603322 |
dabrafenib;pazopanib |
| rs72818987 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Up |
Intronic |
chr5 |
180638270 |
180638270 |
dabrafenib;pazopanib |
| rs3736061 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Up |
Exonic |
chr5 |
180630231 |
180630231 |
dabrafenib;pazopanib |
| rs307826 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Up |
Exonic |
chr5 |
180624003 |
180624003 |
dabrafenib;pazopanib |
| rs72808192 |
ADRA1B |
Adrenergic receptor signaling |
Down |
Intergenic |
chr5 |
159912476 |
159912476 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs921756253 |
PDGFRB |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr5 |
150119471 |
150119471 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs138381982 |
ADRB2 |
Adrenergic receptor signaling |
Down |
Intergenic |
chr5 |
148669073 |
148669073 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs71584073 |
ADRB2 |
Adrenergic receptor signaling |
Down |
Intergenic |
chr5 |
148769855 |
148769855 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs307821 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Down |
Exonic |
chr5 |
180603313 |
180603313 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs307826 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Down |
Exonic |
chr5 |
180624003 |
180624003 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs61730019 |
WWC1 |
Hippo signaling |
Down |
Exonic |
chr5 |
168428039 |
168428039 |
pazopanib |
| rs374274136 |
WWC1 |
Hippo signaling |
Down |
Exonic |
chr5 |
168441786 |
168441786 |
pazopanib |
| rs113709008 |
WWC1 |
Hippo signaling |
Down |
Intronic |
chr5 |
168418301 |
168418301 |
pazopanib |
| rs72818987 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Down |
Intronic |
chr5 |
180638270 |
180638270 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs3736061 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Down |
Exonic |
chr5 |
180630231 |
180630231 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs79620092 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Down |
Exonic |
chr5 |
180603322 |
180603322 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs756863213 |
PDGFRB |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr5 |
150129821 |
150129821 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs307821 |
FLT4 |
Vascular endothelial growth factor receptor signaling |
Up |
Exonic |
chr5 |
180603313 |
180603313 |
dabrafenib;pazopanib |
| rs56257144 |
HMGCS1 |
Cholesterol synthesis |
Up |
Exonic |
chr5 |
43294090 |
43294090 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs150660742 |
PTGER4 |
Prostaglandin E2 receptor signaling |
Down |
Intergenic |
chr5 |
40336542 |
40336542 |
dasatinib;rituximab;ruxolitinib;vemurafenib |
| rs966845 |
PDLIM5 |
Myofibril formation |
Down |
Exonic |
chr4 |
94618116 |
94618116 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs7695247 |
SLC39A8 |
Cellular iron uptake and export |
Up |
Intergenic |
chr4 |
102351603 |
102351603 |
crizotinib;imatinib;ruxolitinib |
| rs12501751 |
VEGFC |
Vascular endothelial growth factor receptor signaling |
Down |
Intergenic |
chr4 |
176668851 |
176668851 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs17006063 |
SCD5 |
Desaturation of fatty acids |
Up |
Exonic |
chr4 |
82660930 |
82660930 |
dabrafenib;lapatinib;pazopanib;sorafenib |
| rs7685117 |
PDGFRA |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr4 |
54295224 |
54295224 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs62311829 |
SCD5 |
Desaturation of fatty acids |
Up |
Intronic |
chr4 |
82749435 |
82749435 |
dabrafenib;lapatinib;pazopanib;sorafenib |
| rs1873778 |
PDGFRA |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr4 |
54274888 |
54274888 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs75541622 |
PDGFC |
Platelet-derived growth factor receptor signaling |
Down |
Intronic |
chr4 |
156892172 |
156892172 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs2228119 |
AGA |
Lysosomal glycoprotein degradation |
Up |
Exonic |
chr4 |
177438806 |
177438806 |
pazopanib |
| rs1734719769 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125408634 |
125408634 |
pazopanib |
| rs181032092 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125451645 |
125451645 |
pazopanib |
| rs36052762 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125320180 |
125320180 |
pazopanib |
| rs552658366 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125434306 |
125434306 |
pazopanib |
| rs6824160 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125481735 |
125481735 |
pazopanib |
| rs7657251 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125320098 |
125320098 |
pazopanib |
| rs988863 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125448717 |
125448717 |
pazopanib |
| rs36069160 |
SLC26A1 |
Chloride transmembrane transport |
Down |
Exonic |
chr4 |
989226 |
989226 |
ponatinib;sunitinib;vandetanib |
| rs200471470 |
SLC26A1 |
Chloride transmembrane transport |
Down |
Exonic |
chr4 |
991551 |
991551 |
ponatinib;sunitinib;vandetanib |
| rs13107595 |
PDLIM5 |
Myofibril formation |
Down |
Exonic |
chr4 |
94657437 |
94657437 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs116757365 |
SCARB2 |
Cellular cholesterol uptake and efflux |
Down |
Intronic |
chr4 |
76194965 |
76194965 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs12501751 |
VEGFC |
Vascular endothelial growth factor receptor signaling |
Up |
Intergenic |
chr4 |
176668851 |
176668851 |
dabrafenib;pazopanib |
| rs35961234 |
KDR |
Vascular endothelial growth factor receptor signaling |
Up |
Exonic |
chr4 |
55080004 |
55080004 |
dabrafenib;pazopanib |
| rs17773354 |
KDR |
Vascular endothelial growth factor receptor signaling |
Up |
Intergenic |
chr4 |
55134413 |
55134413 |
dabrafenib;pazopanib |
| rs13107325 |
SLC39A8 |
Cellular iron uptake and export |
Up |
Exonic |
chr4 |
102267552 |
102267552 |
crizotinib;imatinib;ruxolitinib |
| rs35225200 |
SLC39A8 |
Cellular iron uptake and export |
Up |
Intergenic |
chr4 |
102225731 |
102225731 |
crizotinib;imatinib;ruxolitinib |
| rs13120317 |
KDR |
Vascular endothelial growth factor receptor signaling |
Up |
Intergenic |
chr4 |
55042634 |
55042634 |
dabrafenib;pazopanib |
| rs62324183 |
SLC39A8 |
Cellular iron uptake and export |
Up |
Intergenic |
chr4 |
102103266 |
102103266 |
crizotinib;imatinib;ruxolitinib |
| rs80055204 |
SLC39A8 |
Cellular iron uptake and export |
Up |
Intergenic |
chr4 |
102094853 |
102094853 |
crizotinib;imatinib;ruxolitinib |
| rs12650153 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125452634 |
125452634 |
pazopanib |
| rs72665700 |
PDLIM5 |
Myofibril formation |
Down |
Intergenic |
chr4 |
94359133 |
94359133 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs35961234 |
KDR |
Vascular endothelial growth factor receptor signaling |
Down |
Exonic |
chr4 |
55080004 |
55080004 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs17773354 |
KDR |
Vascular endothelial growth factor receptor signaling |
Down |
Intergenic |
chr4 |
55134413 |
55134413 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs13120317 |
KDR |
Vascular endothelial growth factor receptor signaling |
Down |
Intergenic |
chr4 |
55042634 |
55042634 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs115743950 |
PDLIM5 |
Myofibril formation |
Down |
Exonic |
chr4 |
94575789 |
94575789 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs1608942 |
SCD5 |
Desaturation of fatty acids |
Up |
Intronic |
chr4 |
82671389 |
82671389 |
dabrafenib;lapatinib;pazopanib;sorafenib |
| rs966845 |
PDLIM5 |
Myofibril formation |
Up |
Exonic |
chr4 |
94618116 |
94618116 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs72665700 |
PDLIM5 |
Myofibril formation |
Up |
Intergenic |
chr4 |
94359133 |
94359133 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs13107595 |
PDLIM5 |
Myofibril formation |
Up |
Exonic |
chr4 |
94657437 |
94657437 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs115743950 |
PDLIM5 |
Myofibril formation |
Up |
Exonic |
chr4 |
94575789 |
94575789 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs1054031905 |
AADAT |
Transamination pathways |
Up |
Exonic |
chr4 |
170061961 |
170061961 |
pazopanib |
| rs1014865 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125491177 |
125491177 |
pazopanib |
| rs72681856 |
MFSD8 |
Lysosomal glycoprotein degradation |
Up |
Intronic |
chr4 |
127943212 |
127943212 |
pazopanib |
| rs76491548 |
AGA |
Lysosomal glycoprotein degradation |
Up |
Exonic |
chr4 |
177439657 |
177439657 |
pazopanib |
| rs11732383 |
AADAT |
Transamination pathways |
Up |
Intergenic |
chr4 |
170130476 |
170130476 |
pazopanib |
| rs1014867 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125491736 |
125491736 |
pazopanib |
| rs11724383 |
FAT4 |
Hippo signaling |
Down |
Intergenic |
chr4 |
124742304 |
124742304 |
pazopanib |
| rs12508222 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125449492 |
125449492 |
pazopanib |
| rs147662558 |
FAT4 |
Hippo signaling |
Down |
Exonic |
chr4 |
125490951 |
125490951 |
pazopanib |
| rs6344 |
SLC6A1 |
GABA metabolism |
Up |
Exonic |
chr3 |
11022405 |
11022405 |
axitinib;cabozantinib;imatinib;nilotinib;ruxolitinib;vemurafenib |
| rs149663605 |
TNK2 |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr3 |
195868642 |
195868642 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs116570170 |
BFSP2 |
Epithelial intermediate filament dynamics |
Down |
Intronic |
chr3 |
133413381 |
133413381 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs1553771564 |
MME |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
Intergenic |
chr3 |
155198803 |
155198803 |
axitinib;bosutinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs143348369 |
TNK2 |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr3 |
195867197 |
195867197 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs1056726 |
TNK2 |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr3 |
195868534 |
195868534 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs6805248 |
XIRP1 |
Myofibril formation |
Down |
Exonic |
chr3 |
39188409 |
39188409 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs62244166 |
XIRP1 |
Myofibril formation |
Down |
Exonic |
chr3 |
39187185 |
39187185 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs149791145 |
XIRP1 |
Myofibril formation |
Down |
Intergenic |
chr3 |
39232132 |
39232132 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs6805248 |
XIRP1 |
Myofibril formation |
Up |
Exonic |
chr3 |
39188409 |
39188409 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs62244166 |
XIRP1 |
Myofibril formation |
Up |
Exonic |
chr3 |
39187185 |
39187185 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs149791145 |
XIRP1 |
Myofibril formation |
Up |
Intergenic |
chr3 |
39232132 |
39232132 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs988928079 |
MME |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
Intergenic |
chr3 |
154997731 |
154997731 |
axitinib;bosutinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs61762319 |
MME |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
Exonic |
chr3 |
155084189 |
155084189 |
axitinib;bosutinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs200313650 |
MME |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
Exonic |
chr3 |
155172567 |
155172567 |
axitinib;bosutinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs13091944 |
PFKFB4 |
Glycolysis and Gluconeogenesis |
Down |
Intronic |
chr3 |
48537306 |
48537306 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs78391783 |
WWTR1 |
Hippo signaling |
Down |
Intronic |
chr3 |
149620981 |
149620981 |
pazopanib |
| rs56268728 |
WWTR1 |
Hippo signaling |
Down |
Intronic |
chr3 |
149701376 |
149701376 |
pazopanib |
| rs28763914 |
WWTR1 |
Hippo signaling |
Down |
Exonic |
chr3 |
149527888 |
149527888 |
pazopanib |
| rs115717999 |
WWTR1 |
Hippo signaling |
Down |
Intronic |
chr3 |
149682782 |
149682782 |
pazopanib |
| rs10513355 |
WWTR1 |
Hippo signaling |
Down |
Intronic |
chr3 |
149533572 |
149533572 |
pazopanib |
| rs2073498 |
RASSF1 |
Hippo signaling |
Down |
Exonic |
chr3 |
50332115 |
50332115 |
pazopanib |
| rs147944291 |
RASSF1 |
Hippo signaling |
Down |
Intronic |
chr3 |
50339615 |
50339615 |
pazopanib |
| rs570965109 |
AMOTL2 |
Hippo signaling |
Down |
Exonic |
chr3 |
134360391 |
134360391 |
pazopanib |
| rs763319558 |
PFKFB4 |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr3 |
48556736 |
48556736 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs7615170 |
PFKFB4 |
Glycolysis and Gluconeogenesis |
Down |
Intronic |
chr3 |
48539050 |
48539050 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs145387235 |
LMOD3 |
Thin myofilament organization |
Down |
Exonic |
chr3 |
69118700 |
69118700 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs145387235 |
LMOD3 |
Thin myofilament organization |
Up |
Exonic |
chr3 |
69118700 |
69118700 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs555650704 |
LMOD3 |
Thin myofilament organization |
Up |
Exonic |
chr3 |
69122345 |
69122348 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs900690 |
SCAP |
Cholesterol-sensitive control of SREBP activation |
Down |
Exonic |
chr3 |
47420710 |
47420710 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;gefitinib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs145728787 |
SCAP |
Cholesterol-sensitive control of SREBP activation |
Down |
Intronic |
chr3 |
47461693 |
47461693 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;gefitinib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs7612298 |
DLG1 |
Adrenergic receptor signaling |
Down |
Intergenic |
chr3 |
197032289 |
197032289 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs1776502129 |
DLG1 |
Adrenergic receptor signaling |
Down |
Intronic |
chr3 |
197121795 |
197121795 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs900690 |
SCAP |
Cholesterol-sensitive control of SREBP activation |
Up |
Exonic |
chr3 |
47420710 |
47420710 |
lapatinib;pazopanib;ponatinib;sorafenib;sunitinib |
| rs2692696 |
TF |
Cellular iron uptake and export |
Up |
Exonic |
chr3 |
133766289 |
133766289 |
crizotinib;imatinib;ruxolitinib |
| rs145728787 |
SCAP |
Cholesterol-sensitive control of SREBP activation |
Up |
Intronic |
chr3 |
47461693 |
47461693 |
lapatinib;pazopanib;ponatinib;sorafenib;sunitinib |
| rs141275079 |
DLG1 |
Adrenergic receptor signaling |
Down |
Intronic |
chr3 |
197069377 |
197069381 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs148545588 |
CLCN2 |
Chloride transmembrane transport |
Down |
Exonic |
chr3 |
184353348 |
184353348 |
ponatinib;sunitinib;vandetanib |
| rs118123032 |
CP |
Cellular iron uptake and export |
Up |
Intronic |
chr3 |
149195639 |
149195639 |
crizotinib;imatinib;ruxolitinib |
| rs4264746 |
PDHB |
Citric acid cycle |
Up |
Exonic |
chr3 |
58430811 |
58430811 |
pazopanib |
| rs187763793 |
CP |
Cellular iron uptake and export |
Up |
Intergenic |
chr3 |
149299559 |
149299559 |
crizotinib;imatinib;ruxolitinib |
| rs555650704 |
LMOD3 |
Thin myofilament organization |
Down |
Exonic |
chr3 |
69122345 |
69122348 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs148283280 |
LTF |
Cellular iron uptake and export |
Up |
Exonic |
chr3 |
46450505 |
46450505 |
crizotinib;imatinib;ruxolitinib |
| rs1553665422 |
LTF |
Cellular iron uptake and export |
Up |
Exonic |
chr3 |
46459794 |
46459794 |
crizotinib;imatinib;ruxolitinib |
| rs13075921 |
CP |
Cellular iron uptake and export |
Up |
Intronic |
chr3 |
149197841 |
149197841 |
crizotinib;imatinib;ruxolitinib |
| rs1569207343 |
SEC14L2 |
Cholesterol synthesis |
Down |
Exonic |
chr22 |
30407125 |
30407125 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs1929312899 |
OSM |
Oncostatin-M receptor signaling |
Down |
Exonic |
chr22 |
30263994 |
30263994 |
ruxolitinib;tofacitinib |
| rs2003688 |
PICK1 |
Serine and glycine metabolism |
Up |
Intergenic |
chr22 |
38051629 |
38051629 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs3026681 |
PICK1 |
Serine and glycine metabolism |
Up |
Intergenic |
chr22 |
38056133 |
38056133 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs56263124 |
PDGFB |
Platelet-derived growth factor receptor signaling |
Down |
Intergenic |
chr22 |
39219028 |
39219045 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs55634318 |
PDGFB |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr22 |
39231625 |
39231625 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs9613974 |
NF2 |
Hippo signaling |
Down |
Intergenic |
chr22 |
29588439 |
29588439 |
pazopanib |
| rs73159061 |
NF2 |
Hippo signaling |
Down |
Intronic |
chr22 |
29621104 |
29621104 |
pazopanib |
| rs2530657 |
NF2 |
Hippo signaling |
Down |
Intergenic |
chr22 |
29598403 |
29598403 |
pazopanib |
| rs2003688 |
PICK1 |
Serine and glycine metabolism |
Down |
Intergenic |
chr22 |
38051629 |
38051629 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs1569207343 |
SEC14L2 |
Cholesterol synthesis |
Up |
Exonic |
chr22 |
30407125 |
30407125 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs2063675633 |
PANX2 |
Gap junction organization |
Down |
Exonic |
chr22 |
50178227 |
50178227 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs34915139 |
NEFH |
Axonal intermediate filament dynamics |
Up |
Intronic |
chr22 |
29483928 |
29483928 |
afatinib;axitinib;cetuximab;ruxolitinib;vemurafenib |
| rs59371099 |
NEFH |
Axonal intermediate filament dynamics |
Up |
Exonic |
chr22 |
29489027 |
29489027 |
afatinib;axitinib;cetuximab;ruxolitinib;vemurafenib |
| rs3026681 |
PICK1 |
Serine and glycine metabolism |
Down |
Intergenic |
chr22 |
38056133 |
38056133 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs77784801 |
ABCG1 |
Cellular cholesterol uptake and efflux |
Down |
Intronic |
chr21 |
42291879 |
42291879 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs117288255 |
KCNE2 |
Potassium transmembrane transport |
Up |
Intergenic |
chr21 |
34360188 |
34360188 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs763260521 |
KCNE2 |
Potassium transmembrane transport |
Up |
Intergenic |
chr21 |
34214422 |
34214423 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs1057037 |
PFKL |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr21 |
44313984 |
44313984 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs118169148 |
PFKL |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr21 |
44305863 |
44305863 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs146583875 |
PFKL |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr21 |
44326802 |
44326802 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs147169525 |
PFKL |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr21 |
44326057 |
44326057 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs2047505401 |
PFKL |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr21 |
44326219 |
44326219 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs28550863 |
DYRK1A |
Hippo signaling |
Down |
Utr3 |
chr21 |
37522100 |
37522100 |
pazopanib |
| rs8192708 |
PCK1 |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr20 |
57563565 |
57563565 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs35385772 |
E2F1 |
Restriction point |
Up |
Exonic |
chr20 |
33678328 |
33678328 |
sunitinib;vandetanib |
| rs17344810 |
SLC12A5 |
Potassium transmembrane transport |
Up |
Exonic |
chr20 |
46051854 |
46051854 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs78903141 |
BFSP1 |
Epithelial intermediate filament dynamics |
Down |
Intronic |
chr20 |
17523360 |
17523360 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs77659338 |
SLC12A5 |
Potassium transmembrane transport |
Up |
Exonic |
chr20 |
46035854 |
46035854 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs1568696929 |
BIRC7 |
Inhibition of apoptosis |
Down |
Exonic |
chr20 |
63239388 |
63239388 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs79055277 |
BIRC7 |
Inhibition of apoptosis |
Down |
Exonic |
chr20 |
63238604 |
63238604 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs139573483 |
COL9A3 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr20 |
62826783 |
62826783 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs142639450 |
COL9A3 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr20 |
62819981 |
62819981 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs373605761 |
COL9A3 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr20 |
62817598 |
62817598 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs45628843 |
COL9A3 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr20 |
62827963 |
62827963 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs6084816 |
ADRA1D |
Adrenergic receptor signaling |
Down |
Intergenic |
chr20 |
4644801 |
4644801 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs1751515139 |
BIRC7 |
Inhibition of apoptosis |
Down |
Intergenic |
chr20 |
63225294 |
63225294 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs35385772 |
E2F1 |
Restriction point |
Down |
Exonic |
chr20 |
33678328 |
33678328 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs117688930 |
ADRA1D |
Adrenergic receptor signaling |
Down |
Intergenic |
chr20 |
4426888 |
4426888 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs11537702 |
BFSP1 |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr20 |
17498972 |
17498972 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs6032635 |
SLC12A5 |
Potassium transmembrane transport |
Up |
Exonic |
chr20 |
46049709 |
46049709 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs1553454882 |
SMYD1 |
Myofibril formation |
Down |
Intronic |
chr2 |
88080245 |
88080245 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs35551800 |
INSIG2 |
Cholesterol-sensitive control of SREBP activation |
Up |
Exonic |
chr2 |
118103297 |
118103297 |
lapatinib;pazopanib;ponatinib;sorafenib;sunitinib |
| rs1064512 |
SLC1A4 |
Serine and glycine metabolism |
Up |
Exonic |
chr2 |
64989752 |
64989752 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs56156353 |
RAPGEF4 |
Prostaglandin E2 receptor signaling |
Down |
Intronic |
chr2 |
172888437 |
172888437 |
dasatinib;rituximab;ruxolitinib;vemurafenib |
| rs61741759 |
RAPGEF4 |
Prostaglandin E2 receptor signaling |
Down |
Exonic |
chr2 |
173018795 |
173018795 |
dasatinib;rituximab;ruxolitinib;vemurafenib |
| rs72902264 |
RAPGEF4 |
Prostaglandin E2 receptor signaling |
Down |
Intronic |
chr2 |
172771757 |
172771757 |
dasatinib;rituximab;ruxolitinib;vemurafenib |
| rs765512351 |
CYP27A1 |
Cholesterol synthesis |
Up |
Exonic |
chr2 |
218812299 |
218812299 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs114654835 |
SMYD1 |
Myofibril formation |
Down |
Intronic |
chr2 |
88084970 |
88084970 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs141937046 |
RAPGEF4 |
Prostaglandin E2 receptor signaling |
Down |
Intronic |
chr2 |
172920475 |
172920475 |
dasatinib;rituximab;ruxolitinib;vemurafenib |
| rs6716642 |
CYP27A1 |
Cholesterol synthesis |
Up |
Intronic |
chr2 |
218787096 |
218787096 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs9096 |
COMMD1 |
HIF-1 receptor signaling pathway |
Down |
Exonic |
chr2 |
62135860 |
62135860 |
dabrafenib;pazopanib |
| rs78712307 |
COMMD1 |
HIF-1 receptor signaling pathway |
Down |
Intronic |
chr2 |
62108315 |
62108315 |
dabrafenib;pazopanib |
| rs116129645 |
COMMD1 |
HIF-1 receptor signaling pathway |
Down |
Intronic |
chr2 |
61931442 |
61931442 |
dabrafenib;pazopanib |
| rs61733619 |
CYP27A1 |
Cholesterol synthesis |
Up |
Exonic |
chr2 |
218812967 |
218812967 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs4646534 |
CYP27A1 |
Cholesterol synthesis |
Up |
Intronic |
chr2 |
218782732 |
218782732 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs79950063 |
SLC40A1 |
Cellular iron uptake and export |
Up |
Intergenic |
chr2 |
189478323 |
189478323 |
crizotinib;imatinib;ruxolitinib |
| rs79841817 |
KCNE4 |
Potassium transmembrane transport |
Up |
Intergenic |
chr2 |
223272387 |
223272387 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs71428357 |
ABCA12 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr2 |
214989432 |
214989432 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs147106773 |
AGXT |
Transamination pathways |
Up |
Exonic |
chr2 |
240875160 |
240875160 |
pazopanib |
| rs1553454882 |
SMYD1 |
Myofibril formation |
Up |
Intronic |
chr2 |
88080245 |
88080245 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs4646534 |
CYP27A1 |
Cholesterol synthesis |
Down |
Intronic |
chr2 |
218782732 |
218782732 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs61733619 |
CYP27A1 |
Cholesterol synthesis |
Down |
Exonic |
chr2 |
218812967 |
218812967 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs6716642 |
CYP27A1 |
Cholesterol synthesis |
Down |
Intronic |
chr2 |
218787096 |
218787096 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs765512351 |
CYP27A1 |
Cholesterol synthesis |
Down |
Exonic |
chr2 |
218812299 |
218812299 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs7560008 |
ABCA12 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr2 |
215011442 |
215011442 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs2695342 |
SLC11A1 |
Cellular iron uptake and export |
Up |
Exonic |
chr2 |
218389899 |
218389899 |
crizotinib;imatinib;ruxolitinib |
| rs1468558519 |
RAPGEF4 |
Prostaglandin E2 receptor signaling |
Down |
Intronic |
chr2 |
173028604 |
173028604 |
dasatinib;rituximab;ruxolitinib;vemurafenib |
| rs114654835 |
SMYD1 |
Myofibril formation |
Up |
Intronic |
chr2 |
88084970 |
88084970 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs61754200 |
BIRC6 |
Inhibition of apoptosis |
Down |
Exonic |
chr2 |
32515228 |
32515228 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs149561952 |
ABCA12 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr2 |
214937584 |
214937584 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs78084104 |
KCNE4 |
Potassium transmembrane transport |
Up |
Intergenic |
chr2 |
223565488 |
223565488 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs62188340 |
KCNE4 |
Potassium transmembrane transport |
Up |
Intergenic |
chr2 |
223412804 |
223412804 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs114651183 |
ABCA12 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr2 |
215019368 |
215019368 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs140936029 |
ARL4C |
Cellular cholesterol uptake and efflux |
Down |
Intergenic |
chr2 |
234633505 |
234633505 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs62182122 |
SLC11A1 |
Cellular iron uptake and export |
Up |
Intergenic |
chr2 |
218375512 |
218375512 |
crizotinib;imatinib;ruxolitinib |
| rs61754194 |
BIRC6 |
Inhibition of apoptosis |
Down |
Exonic |
chr2 |
32443563 |
32443563 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs141937046 |
RAPGEF4 |
Adrenergic receptor signaling |
Down |
Intronic |
chr2 |
172920475 |
172920475 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs41291167 |
BIRC6 |
Inhibition of apoptosis |
Down |
Exonic |
chr2 |
32441343 |
32441343 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs113357151 |
HK2 |
Glycolysis and Gluconeogenesis |
Down |
Intergenic |
chr2 |
74829722 |
74829722 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs115402862 |
HK2 |
Glycolysis and Gluconeogenesis |
Down |
Intergenic |
chr2 |
74696517 |
74696517 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs13004591 |
HK2 |
Glycolysis and Gluconeogenesis |
Down |
Intergenic |
chr2 |
74765915 |
74765915 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs139126646 |
HK2 |
Glycolysis and Gluconeogenesis |
Down |
Intergenic |
chr2 |
74820408 |
74820408 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs28363022 |
HK2 |
Glycolysis and Gluconeogenesis |
Down |
Intronic |
chr2 |
74877890 |
74877890 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs374472287 |
BIRC6 |
Inhibition of apoptosis |
Down |
Exonic |
chr2 |
32617748 |
32617748 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs1468558519 |
RAPGEF4 |
Adrenergic receptor signaling |
Down |
Intronic |
chr2 |
173028604 |
173028604 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs56156353 |
RAPGEF4 |
Adrenergic receptor signaling |
Down |
Intronic |
chr2 |
172888437 |
172888437 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs10190755 |
KCNE4 |
Potassium transmembrane transport |
Up |
Intergenic |
chr2 |
223013509 |
223013509 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs10201907 |
KCNE4 |
Potassium transmembrane transport |
Up |
Exonic |
chr2 |
223053094 |
223053094 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs1553528036 |
KCNE4 |
Potassium transmembrane transport |
Up |
Intergenic |
chr2 |
223140386 |
223140386 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs61741759 |
RAPGEF4 |
Adrenergic receptor signaling |
Down |
Exonic |
chr2 |
173018795 |
173018795 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs35551800 |
INSIG2 |
Cholesterol-sensitive control of SREBP activation |
Down |
Exonic |
chr2 |
118103297 |
118103297 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;gefitinib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs72902264 |
RAPGEF4 |
Adrenergic receptor signaling |
Down |
Intronic |
chr2 |
172771757 |
172771757 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs7576974 |
SLC11A1 |
Cellular iron uptake and export |
Up |
Exonic |
chr2 |
218383067 |
218383067 |
crizotinib;imatinib;ruxolitinib |
| rs2049962479 |
BIRC6 |
Inhibition of apoptosis |
Down |
Intronic |
chr2 |
32478038 |
32478038 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs34996177 |
BIRC6 |
Inhibition of apoptosis |
Down |
Exonic |
chr2 |
32415972 |
32415972 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs140684752 |
BIRC6 |
Inhibition of apoptosis |
Down |
Exonic |
chr2 |
32467941 |
32467941 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs150606467 |
PXDN |
Collagen fiber crosslinking |
Down |
Intergenic |
chr2 |
1564606 |
1564606 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs77055995 |
PXDN |
Collagen fiber crosslinking |
Down |
Intergenic |
chr2 |
1754184 |
1754184 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs1064512 |
SLC1A4 |
Serine and glycine metabolism |
Down |
Exonic |
chr2 |
64989752 |
64989752 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs11879910 |
ABCA7 |
Cellular cholesterol uptake and efflux |
Down |
Upstream |
chr19 |
1039992 |
1039992 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs12609791 |
BIRC8 |
Inhibition of apoptosis |
Down |
Ncrna_exonic |
chr19 |
53290635 |
53290635 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs267605268 |
ABCA7 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr19 |
1056919 |
1056919 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs1454735927 |
TNNI3 |
Thin myofilament organization |
Down |
Exonic |
chr19 |
55154042 |
55154042 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs4147918 |
ABCA7 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr19 |
1058177 |
1058177 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs8191416 |
GPI |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr19 |
34393952 |
34393952 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs3729711 |
TNNI3 |
Thin myofilament organization |
Up |
Exonic |
chr19 |
55156279 |
55156279 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs3752233 |
ABCA7 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr19 |
1045174 |
1045174 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs3752239 |
ABCA7 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr19 |
1047538 |
1047538 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs3764644 |
ABCA7 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr19 |
1041853 |
1041853 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs3764647 |
ABCA7 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr19 |
1044713 |
1044713 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs61745734 |
GAPDHS |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr19 |
35538338 |
35538338 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs45513793 |
GAPDHS |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr19 |
35542531 |
35542531 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs45606534 |
ATP1A3 |
Potassium transmembrane transport |
Up |
Exonic |
chr19 |
41970240 |
41970240 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs4147921 |
ABCA7 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr19 |
1062193 |
1062193 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs76199083 |
BCAT2 |
Transamination pathways |
Up |
Intronic |
chr19 |
48797636 |
48797636 |
pazopanib |
| rs146600566 |
ATP1A3 |
Potassium transmembrane transport |
Up |
Exonic |
chr19 |
41975666 |
41975666 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs3729711 |
TNNI3 |
Thin myofilament organization |
Down |
Exonic |
chr19 |
55156279 |
55156279 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs78320196 |
ABCA7 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr19 |
1061805 |
1061805 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs71353933 |
SLC1A5 |
Serine and glycine metabolism |
Up |
Intergenic |
chr19 |
46807632 |
46807632 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs1454735927 |
TNNI3 |
Thin myofilament organization |
Up |
Exonic |
chr19 |
55154042 |
55154042 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs2217342 |
ATP1A3 |
Potassium transmembrane transport |
Up |
Exonic |
chr19 |
41985364 |
41985364 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs1060043 |
SLC1A5 |
Serine and glycine metabolism |
Down |
Exonic |
chr19 |
46775681 |
46775681 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs71353933 |
SLC1A5 |
Serine and glycine metabolism |
Down |
Intergenic |
chr19 |
46807632 |
46807632 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs75955910 |
AXL |
Hippo signaling |
Down |
Intronic |
chr19 |
41231509 |
41231509 |
pazopanib |
| rs35546772 |
AXL |
Hippo signaling |
Down |
Intronic |
chr19 |
41258853 |
41258853 |
pazopanib |
| rs117629091 |
SLC1A5 |
Serine and glycine metabolism |
Down |
Downstream |
chr19 |
46773949 |
46773949 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs117629091 |
SLC1A5 |
Serine and glycine metabolism |
Up |
Downstream |
chr19 |
46773949 |
46773949 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs1060043 |
SLC1A5 |
Serine and glycine metabolism |
Up |
Exonic |
chr19 |
46775681 |
46775681 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs79044169 |
STAT3 |
Leptin receptor signaling |
Up |
Intronic |
chr17 |
42385795 |
42385795 |
lapatinib;trastuzumab |
| rs77310215 |
XAF1 |
Inhibition of apoptosis |
Down |
Intergenic |
chr17 |
6752869 |
6752869 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs182656006 |
XAF1 |
Inhibition of apoptosis |
Down |
Intergenic |
chr17 |
6744858 |
6744858 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs79044169 |
STAT3 |
Leptin receptor signaling |
Down |
Intronic |
chr17 |
42385795 |
42385795 |
axitinib;ruxolitinib;tofacitinib;vemurafenib |
| rs2071214 |
BIRC5 |
Inhibition of apoptosis |
Down |
Exonic |
chr17 |
78223510 |
78223510 |
afatinib;cetuximab;dasatinib;erlotinib;imatinib;rituximab;tofacitinib;vemurafenib |
| rs79044169 |
STAT3 |
Oncostatin-M receptor signaling |
Down |
Intronic |
chr17 |
42385795 |
42385795 |
ruxolitinib;tofacitinib |
| rs1905459373 |
KRT10 |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr17 |
40822284 |
40822284 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs1041089025 |
KRT13 |
Epithelial intermediate filament dynamics |
Down |
Upstream |
chr17 |
41506111 |
41506111 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs117151355 |
KRT13 |
Epithelial intermediate filament dynamics |
Down |
Intronic |
chr17 |
41503472 |
41503472 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs4796697 |
KRT13 |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr17 |
41502942 |
41502942 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs72833704 |
KRT13 |
Epithelial intermediate filament dynamics |
Down |
Intergenic |
chr17 |
41508910 |
41508910 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs6503640 |
KRT14 |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr17 |
41586647 |
41586647 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs113201466 |
KRT19 |
Epithelial intermediate filament dynamics |
Down |
Intergenic |
chr17 |
41534087 |
41534087 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs144791995 |
KRT19 |
Epithelial intermediate filament dynamics |
Down |
Intronic |
chr17 |
41526231 |
41526231 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs111354487 |
PPP1R9B |
Adrenergic receptor signaling |
Down |
Exonic |
chr17 |
50149928 |
50149928 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs1555565615 |
PPP1R9B |
Adrenergic receptor signaling |
Down |
Exonic |
chr17 |
50149421 |
50149421 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs61749924 |
GJC1 |
Gap junction organization |
Down |
Exonic |
chr17 |
44805605 |
44805605 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs61749920 |
STAT5B |
Oncostatin-M receptor signaling |
Down |
Exonic |
chr17 |
42218219 |
42218219 |
ruxolitinib;tofacitinib |
| rs17591972 |
STAT5B |
Oncostatin-M receptor signaling |
Down |
Intronic |
chr17 |
42247426 |
42247426 |
ruxolitinib;tofacitinib |
| rs145218715 |
STAT5B |
Oncostatin-M receptor signaling |
Down |
Intronic |
chr17 |
42265364 |
42265364 |
ruxolitinib;tofacitinib |
| rs116906338 |
STAT5B |
Oncostatin-M receptor signaling |
Down |
Utr3 |
chr17 |
42200124 |
42200124 |
ruxolitinib;tofacitinib |
| rs4925118 |
SREBF1 |
Cholesterol-sensitive control of SREBP activation |
Down |
Intronic |
chr17 |
17835849 |
17835849 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;gefitinib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs35367147 |
SREBF1 |
Cholesterol-sensitive control of SREBP activation |
Down |
Intronic |
chr17 |
17826717 |
17826717 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;gefitinib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs144954037 |
MAPK7 |
Granulocyte-colony stimulating factor receptor signaling |
Up |
Exonic |
chr17 |
19381954 |
19381954 |
bevacizumab;lapatinib;trastuzumab |
| rs79044169 |
STAT3 |
Granulocyte-colony stimulating factor receptor signaling |
Up |
Intronic |
chr17 |
42385795 |
42385795 |
bevacizumab;lapatinib;trastuzumab |
| rs4925118 |
SREBF1 |
Cholesterol-sensitive control of SREBP activation |
Up |
Intronic |
chr17 |
17835849 |
17835849 |
lapatinib;pazopanib;ponatinib;sorafenib;sunitinib |
| rs35367147 |
SREBF1 |
Cholesterol-sensitive control of SREBP activation |
Up |
Intronic |
chr17 |
17826717 |
17826717 |
lapatinib;pazopanib;ponatinib;sorafenib;sunitinib |
| rs144954037 |
MAPK7 |
Granulocyte-colony stimulating factor receptor signaling |
Down |
Exonic |
chr17 |
19381954 |
19381954 |
axitinib;bosutinib;ruxolitinib;tofacitinib;vemurafenib |
| rs79044169 |
STAT3 |
Granulocyte-colony stimulating factor receptor signaling |
Down |
Intronic |
chr17 |
42385795 |
42385795 |
axitinib;bosutinib;ruxolitinib;tofacitinib;vemurafenib |
| rs1567706539 |
KRT10 |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr17 |
40818962 |
40818962 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs1908935125 |
NDEL1 |
Axonal intermediate filament dynamics |
Up |
Intergenic |
chr17 |
8428953 |
8428953 |
afatinib;axitinib;cetuximab;ruxolitinib;vemurafenib |
| rs2230701 |
THRA |
Thyroid hormone receptor signaling |
Up |
Exonic |
chr17 |
40083963 |
40083963 |
bevacizumab |
| rs1028835012 |
ABCA5 |
Cellular cholesterol uptake and efflux |
Down |
Intronic |
chr17 |
69258727 |
69258731 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs144376773 |
ABCA5 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr17 |
69261214 |
69261214 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs11076256 |
GOT2 |
Transamination pathways |
Up |
Exonic |
chr16 |
58718562 |
58718562 |
pazopanib |
| rs17851876 |
SLC12A4 |
Potassium transmembrane transport |
Up |
Exonic |
chr16 |
67945520 |
67945520 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs1597402826 |
GAN |
Axonal intermediate filament dynamics |
Up |
Exonic |
chr16 |
81356881 |
81356881 |
afatinib;axitinib;cetuximab;ruxolitinib;vemurafenib |
| rs1567432298 |
SLC12A4 |
Potassium transmembrane transport |
Up |
Intergenic |
chr16 |
67971840 |
67971840 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs138765798 |
MAPK3 |
HIF-1 receptor signaling pathway |
Down |
Intergenic |
chr16 |
30137438 |
30137438 |
dabrafenib;pazopanib |
| rs112783573 |
MVD |
Cholesterol synthesis |
Up |
Upstream |
chr16 |
88663301 |
88663301 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs61743590 |
CLCN7 |
Chloride transmembrane transport |
Down |
Exonic |
chr16 |
1457275 |
1457275 |
ponatinib;sunitinib;vandetanib |
| rs12708965 |
SLC12A3 |
Chloride transmembrane transport |
Down |
Exonic |
chr16 |
56902407 |
56902407 |
ponatinib;sunitinib;vandetanib |
| rs2229157 |
ABAT |
GABA metabolism |
Up |
Exonic |
chr16 |
8750532 |
8750532 |
axitinib;cabozantinib;imatinib;nilotinib;ruxolitinib;vemurafenib |
| rs112783573 |
MVD |
Cholesterol synthesis |
Down |
Upstream |
chr16 |
88663301 |
88663301 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs753631243 |
SLC12A3 |
Chloride transmembrane transport |
Down |
Exonic |
chr16 |
56870675 |
56870675 |
ponatinib;sunitinib;vandetanib |
| rs5804 |
SLC12A3 |
Chloride transmembrane transport |
Down |
Exonic |
chr16 |
56894607 |
56894607 |
ponatinib;sunitinib;vandetanib |
| rs142199602 |
SLC12A3 |
Chloride transmembrane transport |
Down |
Exonic |
chr16 |
56879592 |
56879592 |
ponatinib;sunitinib;vandetanib |
| rs11558171 |
GOT2 |
Transamination pathways |
Up |
Exonic |
chr16 |
58734225 |
58734225 |
pazopanib |
| rs1566962056 |
ADPGK |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr15 |
72774893 |
72774893 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs78521190 |
SLC12A6 |
Potassium transmembrane transport |
Up |
Intronic |
chr15 |
34260791 |
34260791 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs34149613 |
ADPGK |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr15 |
72752522 |
72752522 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs74663562 |
TPM1 |
Thin myofilament organization |
Up |
Intergenic |
chr15 |
62952071 |
62952071 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs78198340 |
TPM1 |
Thin myofilament organization |
Up |
Intergenic |
chr15 |
62894448 |
62894448 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs41435250 |
LOXL1 |
Collagen fiber crosslinking |
Down |
Exonic |
chr15 |
73927743 |
73927743 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs11558747 |
TPM1 |
Thin myofilament organization |
Down |
Exonic |
chr15 |
63059674 |
63059674 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs74663562 |
TPM1 |
Thin myofilament organization |
Down |
Intergenic |
chr15 |
62952071 |
62952071 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs78198340 |
TPM1 |
Thin myofilament organization |
Down |
Intergenic |
chr15 |
62894448 |
62894448 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs367982647 |
IDH2 |
Citric acid cycle |
Up |
Exonic |
chr15 |
90088397 |
90088397 |
pazopanib |
| rs145186782 |
SLC12A6 |
Potassium transmembrane transport |
Up |
Exonic |
chr15 |
34260929 |
34260929 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs35174018 |
GJD2 |
Gap junction organization |
Down |
Exonic |
chr15 |
34753075 |
34753075 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs78521190 |
SLC12A6 |
Chloride transmembrane transport |
Down |
Intronic |
chr15 |
34260791 |
34260791 |
ponatinib;sunitinib;vandetanib |
| rs145186782 |
SLC12A6 |
Chloride transmembrane transport |
Down |
Exonic |
chr15 |
34260929 |
34260929 |
ponatinib;sunitinib;vandetanib |
| rs118074962 |
SLC12A1 |
Potassium transmembrane transport |
Up |
Intergenic |
chr15 |
48326405 |
48326405 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs1552311 |
SLC12A1 |
Potassium transmembrane transport |
Up |
Exonic |
chr15 |
48288516 |
48288516 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs34964522 |
GJD2 |
Gap junction organization |
Down |
Exonic |
chr15 |
34752556 |
34752556 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs117937239 |
AQP9 |
Water transmembrane transport |
Up |
Intergenic |
chr15 |
58119396 |
58119396 |
afatinib;cetuximab;gefitinib;vemurafenib |
| rs11558747 |
TPM1 |
Thin myofilament organization |
Up |
Exonic |
chr15 |
63059674 |
63059674 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs41435250 |
LOXL1 |
Elastin cross-linking and assembly |
Down |
Exonic |
chr15 |
73927743 |
73927743 |
cabozantinib;cetuximab;crizotinib;erlotinib |
| rs117937239 |
AQP9 |
Water transmembrane transport |
Down |
Intergenic |
chr15 |
58119396 |
58119396 |
dabrafenib;pazopanib;ponatinib |
| rs80200212 |
SLC24A1 |
Potassium transmembrane transport |
Up |
Utr5 |
chr15 |
65642961 |
65642961 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs35571449 |
SLC24A1 |
Potassium transmembrane transport |
Up |
Exonic |
chr15 |
65625017 |
65625017 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs77491889 |
EGLN3 |
HIF-1 receptor signaling pathway |
Down |
Intergenic |
chr14 |
34331275 |
34331275 |
dabrafenib;pazopanib |
| rs1023172539 |
EGLN3 |
HIF-1 receptor signaling pathway |
Down |
Intergenic |
chr14 |
34223333 |
34223333 |
dabrafenib;pazopanib |
| rs35418251 |
ARG2 |
Aspartate and arginine metabolism |
Down |
Exonic |
chr14 |
67642245 |
67642248 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs35618680 |
PCK2 |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr14 |
24103603 |
24103603 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs1256149 |
AKAP5 |
Adrenergic receptor signaling |
Down |
Exonic |
chr14 |
64469002 |
64469002 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs117656327 |
AJUBA |
Hippo signaling |
Down |
Exonic |
chr14 |
22981339 |
22981339 |
pazopanib |
| rs17099141 |
HIF1A |
HIF-1 receptor signaling pathway |
Down |
Exonic |
chr14 |
61727521 |
61727521 |
dabrafenib;pazopanib |
| rs74784375 |
CYP46A1 |
Cholesterol synthesis |
Down |
Intronic |
chr14 |
99716740 |
99716740 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs74784375 |
CYP46A1 |
Cholesterol synthesis |
Up |
Intronic |
chr14 |
99716740 |
99716740 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs2229187 |
PTGER2 |
Prostaglandin E2 receptor signaling |
Down |
Exonic |
chr14 |
52327289 |
52327289 |
dasatinib;rituximab;ruxolitinib;vemurafenib |
| rs1353410 |
PTGER2 |
Prostaglandin E2 receptor signaling |
Down |
Exonic |
chr14 |
52314623 |
52314623 |
dasatinib;rituximab;ruxolitinib;vemurafenib |
| rs941646 |
SLC24A4 |
Potassium transmembrane transport |
Up |
Exonic |
chr14 |
92325911 |
92325911 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs62623445 |
SLC24A4 |
Potassium transmembrane transport |
Up |
Exonic |
chr14 |
92456438 |
92456438 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs12883517 |
SLC24A4 |
Potassium transmembrane transport |
Up |
Intronic |
chr14 |
92369758 |
92369758 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs10133804 |
SLC24A4 |
Potassium transmembrane transport |
Up |
Intronic |
chr14 |
92400561 |
92400561 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs141882615 |
GJA3 |
Gap junction organization |
Down |
Exonic |
chr13 |
20142178 |
20142178 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs1566514592 |
GJA3 |
Gap junction organization |
Down |
Exonic |
chr13 |
20142394 |
20142394 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs55670167 |
RB1 |
Restriction point |
Down |
Intronic |
chr13 |
48338291 |
48338291 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs1276367875 |
RB1 |
Restriction point |
Down |
Intronic |
chr13 |
48399795 |
48399795 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs117078005 |
GJA3 |
Gap junction organization |
Down |
Intergenic |
chr13 |
20134855 |
20134855 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs61950386 |
FLT1 |
Vascular endothelial growth factor receptor signaling |
Down |
Intergenic |
chr13 |
28574516 |
28574516 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs61950386 |
FLT1 |
Vascular endothelial growth factor receptor signaling |
Up |
Intergenic |
chr13 |
28574516 |
28574516 |
dabrafenib;pazopanib |
| rs17626077 |
FLT1 |
Vascular endothelial growth factor receptor signaling |
Down |
Utr3 |
chr13 |
28387515 |
28387515 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs55869942 |
LATS2 |
Hippo signaling |
Down |
Exonic |
chr13 |
20975245 |
20975245 |
pazopanib |
| rs2482090 |
SLC7A1 |
Aspartate and arginine metabolism |
Down |
Exonic |
chr13 |
29517682 |
29517682 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs2482089 |
SLC7A1 |
Aspartate and arginine metabolism |
Down |
Exonic |
chr13 |
29517577 |
29517577 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs55670167 |
RB1 |
Restriction point |
Up |
Intronic |
chr13 |
48338291 |
48338291 |
sunitinib;vandetanib |
| rs117900613 |
SLC7A1 |
Aspartate and arginine metabolism |
Down |
Exonic |
chr13 |
29523280 |
29523280 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs1276367875 |
RB1 |
Restriction point |
Up |
Intronic |
chr13 |
48399795 |
48399795 |
sunitinib;vandetanib |
| rs17626077 |
FLT1 |
Vascular endothelial growth factor receptor signaling |
Up |
Utr3 |
chr13 |
28387515 |
28387515 |
dabrafenib;pazopanib |
| rs11838138 |
NCOR2 |
Thyroid hormone receptor signaling |
Up |
Intronic |
chr12 |
124386783 |
124386783 |
bevacizumab |
| rs183425427 |
MIP |
Water transmembrane transport |
Down |
Intergenic |
chr12 |
56461151 |
56461151 |
dabrafenib;pazopanib;ponatinib |
| rs3217913 |
CCND2 |
Restriction point |
Up |
Intronic |
chr12 |
4298466 |
4298466 |
sunitinib;vandetanib |
| rs2229716 |
SHMT2 |
Serine and glycine metabolism |
Up |
Exonic |
chr12 |
57232799 |
57232799 |
dabrafenib;pazopanib;ponatinib;sorafenib;sunitinib;trametinib;vandetanib |
| rs2229716 |
SHMT2 |
Serine and glycine metabolism |
Down |
Exonic |
chr12 |
57232799 |
57232799 |
afatinib;axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;imatinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs1555301111 |
NCOR2 |
Thyroid hormone receptor signaling |
Up |
Exonic |
chr12 |
124340175 |
124340175 |
bevacizumab |
| rs183425427 |
MIP |
Water transmembrane transport |
Up |
Intergenic |
chr12 |
56461151 |
56461151 |
afatinib;cetuximab;gefitinib;vemurafenib |
| rs1289470049 |
NCOR2 |
Thyroid hormone receptor signaling |
Up |
Intronic |
chr12 |
124428204 |
124428204 |
bevacizumab |
| rs10846679 |
NCOR2 |
Thyroid hormone receptor signaling |
Up |
Exonic |
chr12 |
124473081 |
124473081 |
bevacizumab |
| rs2227277 |
NCOR2 |
Thyroid hormone receptor signaling |
Up |
Exonic |
chr12 |
124336870 |
124336870 |
bevacizumab |
| rs2230944 |
NCOR2 |
Thyroid hormone receptor signaling |
Up |
Exonic |
chr12 |
124336867 |
124336867 |
bevacizumab |
| rs3217913 |
CCND2 |
Restriction point |
Down |
Intronic |
chr12 |
4298466 |
4298466 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs75013047 |
NCOR2 |
Thyroid hormone receptor signaling |
Up |
Intergenic |
chr12 |
124742673 |
124742673 |
bevacizumab |
| rs7978718 |
NCOR2 |
Thyroid hormone receptor signaling |
Up |
Intronic |
chr12 |
124360408 |
124360408 |
bevacizumab |
| rs17374606 |
BCAT1 |
Transamination pathways |
Up |
Exonic |
chr12 |
24901853 |
24901853 |
pazopanib |
| rs377153333 |
A2M |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
Exonic |
chr12 |
9104396 |
9104396 |
axitinib;bosutinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs557037598 |
ANO2 |
Chloride transmembrane transport |
Down |
Intronic |
chr12 |
5580910 |
5580910 |
ponatinib;sunitinib;vandetanib |
| rs73047658 |
ANO2 |
Chloride transmembrane transport |
Down |
Intronic |
chr12 |
5914501 |
5914501 |
ponatinib;sunitinib;vandetanib |
| rs11067532 |
MVK |
Cholesterol synthesis |
Up |
Intergenic |
chr12 |
109621192 |
109621192 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs74336482 |
MVK |
Cholesterol synthesis |
Up |
Intergenic |
chr12 |
109706132 |
109706132 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs78229794 |
MVK |
Cholesterol synthesis |
Up |
Intergenic |
chr12 |
109673199 |
109673199 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs7968544 |
MVK |
Cholesterol synthesis |
Up |
Intergenic |
chr12 |
109621694 |
109621694 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs80345566 |
MVK |
Cholesterol synthesis |
Up |
Intergenic |
chr12 |
109631077 |
109631077 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs11067532 |
MVK |
Cholesterol synthesis |
Down |
Intergenic |
chr12 |
109621192 |
109621192 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs74336482 |
MVK |
Cholesterol synthesis |
Down |
Intergenic |
chr12 |
109706132 |
109706132 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs78229794 |
MVK |
Cholesterol synthesis |
Down |
Intergenic |
chr12 |
109673199 |
109673199 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs7968544 |
MVK |
Cholesterol synthesis |
Down |
Intergenic |
chr12 |
109621694 |
109621694 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs80345566 |
MVK |
Cholesterol synthesis |
Down |
Intergenic |
chr12 |
109631077 |
109631077 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs772660779 |
CS |
Citric acid cycle |
Up |
Intronic |
chr12 |
56299100 |
56299101 |
pazopanib |
| rs149376950 |
ADCY6 |
Adrenergic receptor signaling |
Down |
Exonic |
chr12 |
48775325 |
48775325 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs226405 |
A2M |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
Exonic |
chr12 |
9095637 |
9095637 |
axitinib;bosutinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs2228222 |
A2M |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
Exonic |
chr12 |
9101645 |
9101645 |
axitinib;bosutinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs1938805037 |
A2M |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
Down |
Exonic |
chr12 |
9112420 |
9112420 |
axitinib;bosutinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs872103 |
CS |
Citric acid cycle |
Up |
Intronic |
chr12 |
56274390 |
56274390 |
pazopanib |
| rs11550887 |
TEAD4 |
Hippo signaling |
Down |
Exonic |
chr12 |
3038037 |
3038037 |
pazopanib |
| rs7956809 |
KRT4 |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr12 |
52808399 |
52808399 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs11170164 |
KRT5 |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr12 |
52519884 |
52519884 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs368067895 |
KRT7 |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr12 |
52248697 |
52248697 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs73109221 |
KRT7 |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr12 |
52248733 |
52248733 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs577294 |
SLC6A13 |
GABA metabolism |
Up |
Exonic |
chr12 |
224027 |
224027 |
axitinib;cabozantinib;imatinib;nilotinib;ruxolitinib;vemurafenib |
| rs11552507 |
PFKM |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr12 |
48132936 |
48132936 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs1650294 |
LDHB |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr12 |
21644095 |
21644095 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs5889 |
SCARB1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr12 |
124814331 |
124814331 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs2016123 |
RAPGEF3 |
Adrenergic receptor signaling |
Down |
Exonic |
chr12 |
47751142 |
47751142 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs12369170 |
RAPGEF3 |
Adrenergic receptor signaling |
Down |
Intergenic |
chr12 |
47733303 |
47733303 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs73304423 |
RAPGEF3 |
Adrenergic receptor signaling |
Down |
Upstream |
chr12 |
47759349 |
47759349 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs3730064 |
ADCY6 |
Adrenergic receptor signaling |
Down |
Exonic |
chr12 |
48782799 |
48782799 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs200843603 |
SCARB1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr12 |
124778478 |
124778478 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs4238001 |
SCARB1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr12 |
124863717 |
124863717 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs56719421 |
IL31 |
Oncostatin-M receptor signaling |
Down |
Exonic |
chr12 |
122173945 |
122173945 |
ruxolitinib;tofacitinib |
| rs75013047 |
SCARB1 |
Cellular cholesterol uptake and efflux |
Down |
Intergenic |
chr12 |
124742673 |
124742673 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs558272065 |
CD163 |
Cellular iron uptake and export |
Up |
Intergenic |
chr12 |
7606475 |
7606475 |
crizotinib;imatinib;ruxolitinib |
| rs73064608 |
CD163 |
Cellular iron uptake and export |
Up |
Intergenic |
chr12 |
7640798 |
7640798 |
crizotinib;imatinib;ruxolitinib |
| rs75587749 |
CD163 |
Cellular iron uptake and export |
Up |
Intergenic |
chr12 |
7462344 |
7462344 |
crizotinib;imatinib;ruxolitinib |
| rs79284771 |
CD163 |
Cellular iron uptake and export |
Up |
Intergenic |
chr12 |
7452506 |
7452506 |
crizotinib;imatinib;ruxolitinib |
| rs7980201 |
CD163 |
Cellular iron uptake and export |
Up |
Exonic |
chr12 |
7487993 |
7487993 |
crizotinib;imatinib;ruxolitinib |
| rs445520 |
SLC11A2 |
Cellular iron uptake and export |
Up |
Exonic |
chr12 |
51009122 |
51009122 |
crizotinib;imatinib;ruxolitinib |
| rs3741901 |
ANO2 |
Chloride transmembrane transport |
Down |
Exonic |
chr12 |
5921135 |
5921135 |
ponatinib;sunitinib;vandetanib |
| rs35027803 |
PANX3 |
Gap junction organization |
Down |
Exonic |
chr11 |
124611598 |
124611598 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs117771288 |
PC |
Glycolysis and Gluconeogenesis |
Down |
Intronic |
chr11 |
66933879 |
66933879 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs34237602 |
PANX3 |
Gap junction organization |
Down |
Exonic |
chr11 |
124619671 |
124619671 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs371253391 |
PANX1 |
Gap junction organization |
Down |
Intronic |
chr11 |
94157152 |
94157152 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs35045740 |
PDGFD |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr11 |
103947667 |
103947667 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs149791167 |
PANX1 |
Gap junction organization |
Down |
Intergenic |
chr11 |
94121524 |
94121524 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs113126481 |
ARRB1 |
Adrenergic receptor signaling |
Down |
Intergenic |
chr11 |
75371264 |
75371264 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs144385608 |
ARRB1 |
Adrenergic receptor signaling |
Down |
Intergenic |
chr11 |
75368848 |
75368848 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs1789680 |
ARRB1 |
Adrenergic receptor signaling |
Down |
Intronic |
chr11 |
75279661 |
75279661 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs3862792 |
CCND1 |
Restriction point |
Down |
Exonic |
chr11 |
69648088 |
69648088 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs7930349 |
FADS3 |
Desaturation of fatty acids |
Up |
Intronic |
chr11 |
61881739 |
61881739 |
dabrafenib;lapatinib;pazopanib;sorafenib |
| rs61897795 |
FADS2 |
Desaturation of fatty acids |
Up |
Intronic |
chr11 |
61850697 |
61850697 |
dabrafenib;lapatinib;pazopanib;sorafenib |
| rs756804034 |
SDHD |
Citric acid cycle |
Up |
Exonic |
chr11 |
112093136 |
112093136 |
pazopanib |
| rs117695734 |
SDHD |
Citric acid cycle |
Up |
Intergenic |
chr11 |
112121550 |
112121550 |
pazopanib |
| rs11214078 |
SDHD |
Citric acid cycle |
Up |
Intronic |
chr11 |
112091982 |
112091982 |
pazopanib |
| rs4937001 |
DLAT |
Citric acid cycle |
Up |
Intronic |
chr11 |
112057329 |
112057329 |
pazopanib |
| rs56271783 |
VEGFB |
Vascular endothelial growth factor receptor signaling |
Down |
Intronic |
chr11 |
64237251 |
64237251 |
bosutinib;crizotinib;dasatinib;erlotinib;nilotinib |
| rs15790 |
SAA1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr11 |
18269765 |
18269765 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs1671926 |
SAA1 |
Cellular cholesterol uptake and efflux |
Down |
Exonic |
chr11 |
18269333 |
18269333 |
dabrafenib;lapatinib;sunitinib;vandetanib |
| rs56271783 |
VEGFB |
Vascular endothelial growth factor receptor signaling |
Up |
Intronic |
chr11 |
64237251 |
64237251 |
dabrafenib;pazopanib |
| rs113763856 |
ANO1 |
Chloride transmembrane transport |
Down |
Intergenic |
chr11 |
69960979 |
69960979 |
ponatinib;sunitinib;vandetanib |
| rs2186797 |
ANO1 |
Chloride transmembrane transport |
Down |
Exonic |
chr11 |
70161664 |
70161664 |
ponatinib;sunitinib;vandetanib |
| rs34064841 |
ANO1 |
Chloride transmembrane transport |
Down |
Exonic |
chr11 |
70187920 |
70187920 |
ponatinib;sunitinib;vandetanib |
| rs11020968 |
AMOTL1 |
Hippo signaling |
Down |
Exonic |
chr11 |
94869249 |
94869249 |
pazopanib |
| rs11607722 |
KCNE3 |
Potassium transmembrane transport |
Up |
Intergenic |
chr11 |
74451881 |
74451881 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs559903574 |
FOSL1 |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr11 |
65900322 |
65900322 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs11824542 |
PDGFD |
Platelet-derived growth factor receptor signaling |
Down |
Intronic |
chr11 |
104039421 |
104039421 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs3862792 |
CCND1 |
Restriction point |
Up |
Exonic |
chr11 |
69648088 |
69648088 |
sunitinib;vandetanib |
| rs144176758 |
PDGFD |
Platelet-derived growth factor receptor signaling |
Down |
Exonic |
chr11 |
103947710 |
103947710 |
lapatinib;pazopanib;ponatinib;sorafenib;trametinib;trastuzumab;vandetanib |
| rs761748692 |
ABCC8 |
Potassium transmembrane transport |
Up |
Exonic |
chr11 |
17442813 |
17442813 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs1272189 |
AMOTL1 |
Hippo signaling |
Down |
Intergenic |
chr11 |
94910778 |
94910778 |
pazopanib |
| rs933922 |
TEAD1 |
Hippo signaling |
Down |
Intergenic |
chr11 |
12556744 |
12556744 |
pazopanib |
| rs142308981 |
YAP1 |
Hippo signaling |
Down |
Intronic |
chr11 |
102227270 |
102227270 |
pazopanib |
| rs149861153 |
ABCC8 |
Potassium transmembrane transport |
Up |
Exonic |
chr11 |
17402699 |
17402699 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs767180765 |
NEU3 |
Lysosomal glycoprotein degradation |
Up |
Exonic |
chr11 |
75005829 |
75005829 |
pazopanib |
| rs179422 |
KCNQ1 |
Potassium transmembrane transport |
Up |
Intronic |
chr11 |
2513830 |
2513830 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs2283210 |
KCNQ1 |
Potassium transmembrane transport |
Up |
Intronic |
chr11 |
2726675 |
2726675 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs200138397 |
TPP1 |
Lysosomal glycoprotein degradation |
Up |
Exonic |
chr11 |
6616751 |
6616751 |
pazopanib |
| rs7115499 |
NEU3 |
Lysosomal glycoprotein degradation |
Up |
Exonic |
chr11 |
74994557 |
74994557 |
pazopanib |
| rs138489397 |
NEU3 |
Lysosomal glycoprotein degradation |
Up |
Intergenic |
chr11 |
75046220 |
75046220 |
pazopanib |
| rs11236283 |
NEU3 |
Lysosomal glycoprotein degradation |
Up |
Exonic |
chr11 |
75004373 |
75004373 |
pazopanib |
| rs138102367 |
NEU3 |
Lysosomal glycoprotein degradation |
Up |
Intergenic |
chr11 |
75019154 |
75019154 |
pazopanib |
| rs1588979812 |
FXYD4 |
Potassium transmembrane transport |
Up |
Intergenic |
chr10 |
43370253 |
43370253 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs41277370 |
NEBL |
Thin myofilament organization |
Down |
Exonic |
chr10 |
20845353 |
20845353 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs61851538 |
NEBL |
Thin myofilament organization |
Up |
Intergenic |
chr10 |
21324141 |
21324141 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs41277370 |
NEBL |
Thin myofilament organization |
Up |
Exonic |
chr10 |
20845353 |
20845353 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs4025981 |
NEBL |
Thin myofilament organization |
Up |
Exonic |
chr10 |
20850460 |
20850460 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs2296614 |
NEBL |
Thin myofilament organization |
Up |
Exonic |
chr10 |
20785795 |
20785795 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs12217637 |
NEBL |
Thin myofilament organization |
Up |
Intronic |
chr10 |
20947306 |
20947306 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs11012394 |
NEBL |
Thin myofilament organization |
Up |
Intronic |
chr10 |
20923823 |
20923823 |
afatinib;axitinib;bosutinib;ceritinib;cetuximab;crizotinib;dasatinib;imatinib |
| rs41307500 |
FXYD4 |
Potassium transmembrane transport |
Up |
Exonic |
chr10 |
43375710 |
43375710 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs11012394 |
NEBL |
Thin myofilament organization |
Down |
Intronic |
chr10 |
20923823 |
20923823 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs12217637 |
NEBL |
Thin myofilament organization |
Down |
Intronic |
chr10 |
20947306 |
20947306 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs2296614 |
NEBL |
Thin myofilament organization |
Down |
Exonic |
chr10 |
20785795 |
20785795 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs4025981 |
NEBL |
Thin myofilament organization |
Down |
Exonic |
chr10 |
20850460 |
20850460 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs113538766 |
PFKFB3 |
Glycolysis and Gluconeogenesis |
Down |
Intergenic |
chr10 |
6273181 |
6273181 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs61851538 |
NEBL |
Thin myofilament organization |
Down |
Intergenic |
chr10 |
21324141 |
21324141 |
bevacizumab;dabrafenib;lapatinib;ponatinib;sunitinib;trametinib |
| rs11000727 |
MYOZ1 |
Myofibril formation |
Down |
Intergenic |
chr10 |
73642873 |
73642873 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs11000727 |
MYOZ1 |
Myofibril formation |
Up |
Intergenic |
chr10 |
73642873 |
73642873 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs11817777 |
GOT1 |
Transamination pathways |
Up |
Intergenic |
chr10 |
99504835 |
99504835 |
pazopanib |
| rs142879930 |
SCD |
Desaturation of fatty acids |
Up |
Intergenic |
chr10 |
100333871 |
100333871 |
dabrafenib;lapatinib;pazopanib;sorafenib |
| rs12359173 |
PFKFB3 |
Restriction point |
Up |
Intronic |
chr10 |
6191208 |
6191208 |
sunitinib;vandetanib |
| rs113538766 |
PFKFB3 |
Restriction point |
Up |
Intergenic |
chr10 |
6273181 |
6273181 |
sunitinib;vandetanib |
| rs12359173 |
PFKFB3 |
Glycolysis and Gluconeogenesis |
Down |
Intronic |
chr10 |
6191208 |
6191208 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs75707357 |
HK1 |
Glycolysis and Gluconeogenesis |
Down |
Intronic |
chr10 |
69371796 |
69371796 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs2230271 |
PFKFB3 |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr10 |
6220739 |
6220739 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs2306302 |
PFKP |
Glycolysis and Gluconeogenesis |
Down |
Exonic |
chr10 |
3112269 |
3112269 |
axitinib;bosutinib;cabozantinib;ceritinib;dasatinib;erlotinib;gefitinib;imatinib;rituximab;vemurafenib |
| rs2230271 |
PFKFB3 |
Restriction point |
Up |
Exonic |
chr10 |
6220739 |
6220739 |
sunitinib;vandetanib |
| rs17186196 |
ADRA2A |
Adrenergic receptor signaling |
Down |
Intergenic |
chr10 |
111072029 |
111072029 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs113538766 |
PFKFB3 |
Restriction point |
Down |
Intergenic |
chr10 |
6273181 |
6273181 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs12359173 |
PFKFB3 |
Restriction point |
Down |
Intronic |
chr10 |
6191208 |
6191208 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs2230271 |
PFKFB3 |
Restriction point |
Down |
Exonic |
chr10 |
6220739 |
6220739 |
axitinib;bosutinib;dasatinib;imatinib;vemurafenib |
| rs2230349 |
GRK5 |
Adrenergic receptor signaling |
Down |
Exonic |
chr10 |
119436823 |
119436823 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs762241331 |
CUL2 |
HIF-1 receptor signaling pathway |
Down |
Exonic |
chr10 |
35071228 |
35071228 |
dabrafenib;pazopanib |
| rs1556234 |
GAD2 |
GABA metabolism |
Up |
Exonic |
chr10 |
26270642 |
26270642 |
axitinib;cabozantinib;imatinib;nilotinib;ruxolitinib;vemurafenib |
| rs149742560 |
GAD2 |
GABA metabolism |
Up |
Exonic |
chr10 |
26292987 |
26292987 |
axitinib;cabozantinib;imatinib;nilotinib;ruxolitinib;vemurafenib |
| rs55834629 |
HIF1AN |
HIF-1 receptor signaling pathway |
Down |
Intergenic |
chr10 |
100681693 |
100681693 |
dabrafenib;pazopanib |
| rs79242821 |
HIF1AN |
HIF-1 receptor signaling pathway |
Down |
Intergenic |
chr10 |
100613052 |
100613052 |
dabrafenib;pazopanib |
| rs11190623 |
HIF1AN |
HIF-1 receptor signaling pathway |
Down |
Intergenic |
chr10 |
100617772 |
100617772 |
dabrafenib;pazopanib |
| rs11190479 |
SCD |
Desaturation of fatty acids |
Up |
Intergenic |
chr10 |
100346008 |
100346008 |
dabrafenib;lapatinib;pazopanib;sorafenib |
| rs150926317 |
DDAH1 |
Aspartate and arginine metabolism |
Down |
Intronic |
chr1 |
85473633 |
85473633 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs17127565 |
DDAH1 |
Aspartate and arginine metabolism |
Down |
Intronic |
chr1 |
85439279 |
85439279 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs34784461 |
DHCR24 |
Cholesterol synthesis |
Up |
Intergenic |
chr1 |
54908733 |
54908735 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs55648410 |
ATP1A4 |
Potassium transmembrane transport |
Up |
Intronic |
chr1 |
160167239 |
160167239 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs77312858 |
LEPR |
Leptin receptor signaling |
Down |
Intergenic |
chr1 |
65693320 |
65693320 |
axitinib;ruxolitinib;tofacitinib;vemurafenib |
| rs777590826 |
MYOG |
Myofibril formation |
Down |
Exonic |
chr1 |
203085574 |
203085574 |
bevacizumab;dabrafenib;pazopanib;ponatinib;sorafenib |
| rs531706012 |
DDAH1 |
Aspartate and arginine metabolism |
Down |
Intronic |
chr1 |
85347002 |
85347002 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs75927365 |
DDAH1 |
Aspartate and arginine metabolism |
Down |
Intronic |
chr1 |
85562147 |
85562147 |
ceritinib;cetuximab;dasatinib;imatinib;regorafenib;ruxolitinib;vemurafenib |
| rs146047856 |
NES |
Axonal intermediate filament dynamics |
Up |
Exonic |
chr1 |
156669485 |
156669485 |
afatinib;axitinib;cetuximab;ruxolitinib;vemurafenib |
| rs2282442 |
NES |
Axonal intermediate filament dynamics |
Up |
Exonic |
chr1 |
156672871 |
156672871 |
afatinib;axitinib;cetuximab;ruxolitinib;vemurafenib |
| rs777590826 |
MYOG |
Myofibril formation |
Up |
Exonic |
chr1 |
203085574 |
203085574 |
afatinib;axitinib;cetuximab;dasatinib;tofacitinib |
| rs143771867 |
KCNK2 |
Potassium transmembrane transport |
Up |
Intergenic |
chr1 |
214723368 |
214723368 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs4278369 |
NES |
Axonal intermediate filament dynamics |
Up |
Exonic |
chr1 |
156676876 |
156676876 |
afatinib;axitinib;cetuximab;ruxolitinib;vemurafenib |
| rs883424 |
NES |
Axonal intermediate filament dynamics |
Up |
Intergenic |
chr1 |
156663542 |
156663542 |
afatinib;axitinib;cetuximab;ruxolitinib;vemurafenib |
| rs41269113 |
AKR1A1 |
Polyol pathway |
Down |
Exonic |
chr1 |
45566871 |
45566871 |
bevacizumab |
| rs1144566 |
RGS16 |
Adrenergic receptor signaling |
Down |
Exonic |
chr1 |
182600491 |
182600491 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs17846715 |
ATP1A2 |
Potassium transmembrane transport |
Up |
Exonic |
chr1 |
160135577 |
160135577 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs72640280 |
NPPB |
Natriuretic peptide receptor signaling |
Up |
Intergenic |
chr1 |
11883735 |
11883735 |
axitinib;bosutinib;crizotinib;dasatinib;nilotinib;tofacitinib |
| rs13305996 |
NPR1 |
Natriuretic peptide receptor signaling |
Up |
Exonic |
chr1 |
153679124 |
153679124 |
axitinib;bosutinib;crizotinib;dasatinib;nilotinib;tofacitinib |
| rs11586015 |
GPR3 |
Adrenergic receptor signaling |
Down |
Exonic |
chr1 |
27393849 |
27393849 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs115462819 |
AQP10 |
Water transmembrane transport |
Down |
Intergenic |
chr1 |
154293485 |
154293485 |
dabrafenib;pazopanib;ponatinib |
| rs2016587303 |
GPR3 |
Adrenergic receptor signaling |
Down |
Intergenic |
chr1 |
27400771 |
27400771 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs2230880 |
GPR3 |
Adrenergic receptor signaling |
Down |
Exonic |
chr1 |
27394569 |
27394569 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs1669682199 |
NPR1 |
Natriuretic peptide receptor signaling |
Up |
Exonic |
chr1 |
153679113 |
153679113 |
axitinib;bosutinib;crizotinib;dasatinib;nilotinib;tofacitinib |
| rs115462819 |
AQP10 |
Water transmembrane transport |
Up |
Intergenic |
chr1 |
154293485 |
154293485 |
afatinib;cetuximab;gefitinib;vemurafenib |
| rs17127063 |
JAK1 |
Oncostatin-M receptor signaling |
Down |
Exonic |
chr1 |
64846659 |
64846659 |
ruxolitinib;tofacitinib |
| rs4652734 |
RGS16 |
Adrenergic receptor signaling |
Down |
Downstream |
chr1 |
182598384 |
182598384 |
bevacizumab;dabrafenib;lapatinib;ponatinib |
| rs17368402 |
ATP1A4 |
Potassium transmembrane transport |
Up |
Exonic |
chr1 |
160164266 |
160164266 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs73025536 |
ATP1A4 |
Potassium transmembrane transport |
Up |
Intronic |
chr1 |
160163817 |
160163817 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs625549 |
ATP1A4 |
Potassium transmembrane transport |
Up |
Exonic |
chr1 |
160171406 |
160171406 |
bevacizumab;lapatinib;trametinib;trastuzumab |
| rs11583958 |
GJA5 |
Gap junction organization |
Down |
Intergenic |
chr1 |
147819603 |
147819603 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs764851668 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Exonic |
chr1 |
11944590 |
11944590 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs879690 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Exonic |
chr1 |
11974748 |
11974748 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs879691 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Exonic |
chr1 |
11974757 |
11974757 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs12723276 |
COL9A2 |
Collagen fibril organization by fibril-associated bridges |
Up |
Intergenic |
chr1 |
40331818 |
40331818 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs140041506 |
COL9A2 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr1 |
40301271 |
40301271 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs2228567 |
COL9A2 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr1 |
40307451 |
40307451 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs2229826 |
COL9A2 |
Collagen fibril organization by fibril-associated bridges |
Up |
Exonic |
chr1 |
40301251 |
40301251 |
axitinib;bosutinib;cabozantinib;cetuximab;dasatinib;nilotinib;regorafenib;rituximab;ruxolitinib;tofacitinib;vemurafenib |
| rs113996374 |
TCHH |
Epithelial intermediate filament dynamics |
Down |
Intergenic |
chr1 |
152140906 |
152140906 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs2515663 |
TCHH |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr1 |
152113029 |
152113029 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs3134814 |
TCHH |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr1 |
152112508 |
152112508 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs6680692 |
TCHH |
Epithelial intermediate filament dynamics |
Down |
Exonic |
chr1 |
152111563 |
152111563 |
afatinib;axitinib;cabozantinib;ceritinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib;nilotinib;tofacitinib;vemurafenib |
| rs41266431 |
GJA4 |
Gap junction organization |
Down |
Exonic |
chr1 |
34794601 |
34794601 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs7513651 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Intronic |
chr1 |
11939067 |
11939067 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs144130765 |
GJA5 |
Gap junction organization |
Down |
Intergenic |
chr1 |
147774984 |
147774984 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs782332416 |
GJA5 |
Gap junction organization |
Down |
Exonic |
chr1 |
147758225 |
147758225 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs11583958 |
GJA8 |
Gap junction organization |
Down |
Intergenic |
chr1 |
147819603 |
147819603 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs144130765 |
GJA8 |
Gap junction organization |
Down |
Intergenic |
chr1 |
147774984 |
147774984 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs148324509 |
GJB3 |
Gap junction organization |
Down |
Intergenic |
chr1 |
34773459 |
34773459 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs35983826 |
GJB3 |
Gap junction organization |
Down |
Exonic |
chr1 |
34785560 |
34785560 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs148324509 |
GJB4 |
Gap junction organization |
Down |
Intergenic |
chr1 |
34773459 |
34773459 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs9426009 |
GJB4 |
Gap junction organization |
Down |
Exonic |
chr1 |
34761561 |
34761561 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs4653910 |
GJC2 |
Gap junction organization |
Down |
Exonic |
chr1 |
228158724 |
228158724 |
bevacizumab;dabrafenib;pazopanib;ponatinib;vandetanib |
| rs17127063 |
JAK1 |
Granulocyte-colony stimulating factor receptor signaling |
Down |
Exonic |
chr1 |
64846659 |
64846659 |
axitinib;bosutinib;ruxolitinib;tofacitinib;vemurafenib |
| rs17127063 |
JAK1 |
Granulocyte-colony stimulating factor receptor signaling |
Up |
Exonic |
chr1 |
64846659 |
64846659 |
bevacizumab;lapatinib;trastuzumab |
| rs1570963601 |
SDHB |
Citric acid cycle |
Up |
Exonic |
chr1 |
17054002 |
17054002 |
pazopanib |
| rs139248801 |
PMVK |
Cholesterol synthesis |
Up |
Exonic |
chr1 |
154929049 |
154929049 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs61811879 |
PMVK |
Cholesterol synthesis |
Up |
Intergenic |
chr1 |
154877185 |
154877185 |
dabrafenib;lapatinib;pazopanib;sorafenib;sunitinib;vandetanib |
| rs34784461 |
DHCR24 |
Cholesterol synthesis |
Down |
Intergenic |
chr1 |
54908733 |
54908735 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs184758181 |
KHDRBS1 |
Leptin receptor signaling |
Down |
Intergenic |
chr1 |
31946144 |
31946144 |
axitinib;ruxolitinib;tofacitinib;vemurafenib |
| rs138227311 |
KHDRBS1 |
Leptin receptor signaling |
Down |
Intergenic |
chr1 |
31986479 |
31986479 |
axitinib;ruxolitinib;tofacitinib;vemurafenib |
| rs77312858 |
LEPR |
Leptin receptor signaling |
Up |
Intergenic |
chr1 |
65693320 |
65693320 |
lapatinib;trastuzumab |
| rs34641586 |
KHDRBS1 |
Leptin receptor signaling |
Up |
Intergenic |
chr1 |
31979791 |
31979791 |
lapatinib;trastuzumab |
| rs184758181 |
KHDRBS1 |
Leptin receptor signaling |
Up |
Intergenic |
chr1 |
31946144 |
31946144 |
lapatinib;trastuzumab |
| rs139248801 |
PMVK |
Cholesterol synthesis |
Down |
Exonic |
chr1 |
154929049 |
154929049 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs61811879 |
PMVK |
Cholesterol synthesis |
Down |
Intergenic |
chr1 |
154877185 |
154877185 |
afatinib;axitinib;bosutinib;cetuximab;crizotinib;dasatinib;gefitinib;tofacitinib;vemurafenib |
| rs138227311 |
KHDRBS1 |
Leptin receptor signaling |
Up |
Intergenic |
chr1 |
31986479 |
31986479 |
lapatinib;trastuzumab |
| rs11541235 |
SDHB |
Citric acid cycle |
Up |
Exonic |
chr1 |
17028723 |
17028723 |
pazopanib |
| rs34641586 |
KHDRBS1 |
Leptin receptor signaling |
Down |
Intergenic |
chr1 |
31979791 |
31979791 |
axitinib;ruxolitinib;tofacitinib;vemurafenib |
| rs4638103 |
SDHC |
Citric acid cycle |
Up |
Intergenic |
chr1 |
161476187 |
161476187 |
pazopanib |
| rs5671 |
PTGER3 |
Prostaglandin E2 receptor signaling |
Down |
Exonic |
chr1 |
71046960 |
71046960 |
dasatinib;rituximab;ruxolitinib;vemurafenib |
| rs61749332 |
PTPN14 |
Hippo signaling |
Down |
Exonic |
chr1 |
214369548 |
214369548 |
pazopanib |
| rs114986084 |
PTPN14 |
Hippo signaling |
Down |
Exonic |
chr1 |
214383467 |
214383467 |
pazopanib |
| rs145790937 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Intronic |
chr1 |
11938121 |
11938121 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs2230898 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Exonic |
chr1 |
11966298 |
11966298 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs34878020 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Exonic |
chr1 |
11949854 |
11949854 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs35460537 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Exonic |
chr1 |
11970702 |
11970702 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs534978828 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Exonic |
chr1 |
11944618 |
11944618 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs60651659 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Intronic |
chr1 |
11972338 |
11972338 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
| rs72640295 |
PLOD1 |
Collagen fiber crosslinking |
Down |
Intronic |
chr1 |
11936480 |
11936480 |
axitinib;cabozantinib;cetuximab;crizotinib;dasatinib;erlotinib;gefitinib;imatinib |
